Molecular cloning of HIV-1 from immortalized cell lines

Description

TERMINOLOGY

The causative agent of acquired immune deficiency syndrome (AIDS) has been known as human T-lymphotropic virus type III (HTLV-III) and as human immunodeficiency virus (HIV). The virus, in accord with the newer practice, will be called HIV except in some instances where a deposit relating to the organism has been made using the earlier terminology.

BRIEF DESCRIPTION OF THE INVENTION

The cultivation of viruses using molecular clones provides a dependable source of virus for study of the natural virus and for preparation of diagnostic and immunogenic products of the virus. The isolation of virus believed to be the causative agent of AIDS was reported by Barre-Sinoussi, et al. in Science, Vol. 220, at pages 868-870 (1983). However, no reproduction of the virus in an immortalized cell line is disclosed in that publication. HIV is highly cytopathic to the cells which it infects in nature. This is one characteristic which differentiates HIV from related retroviruses such as HTLV-I and HTLV-II. HIV is further characterized by variation of its genome in nature. Gallo, et al. discovered cell lines useful for continuous production of the virus. The use of such cell lines which are CD-4 positive cells was disclosed in U.S. patent application Ser. No. 06/652,599, which issued as U.S. Pat. No. 4,652,599. The disclosure of that patent is incorporated herein by reference. The disclosure herein provides means for producing clones of virus which are grown in the immortalized cell lines.

The infectious clones of the inventions are useful for producing specific viral proteins in both eukaryotic and prokaryotic systems for use in diagnostic evaluation and for vaccine development. The infectious clones also provide a source of homogeneous viral particles for use in evaluation of vaccines.

While HXB2 and HXB3 were shown to be non-infectious or only mildly infectious, infectious clones which have been derived therefrom are disclosed. Transfection of the derivative clones into bacteria provides a means for amplifications of the genome of these clones.

It is the object of this invention to provide a reliable source of HIV, viral particles, proteins, and antibodies by preparation of clones containing essentially the entire genome of the HIV. The virus or viral fragments produced in immortalized cell lines are useful as probes to detect HIV viral sequences in HIV strains isolated from patients. By use of such probes the variant strains of HIV can be studied as a means of determining source of the disease in an individual. Such determination of source is vital in evaluating means of transmission of this disease.

It is a further object of the invention to provide reliable sources of viral products for use as immunogens and diagnostic agents.

BACKGROUND OF THE INVENTION

The characterization of HIV as the causative agent of AIDS by Barre-Sinoussi, et al. [Science, Vol. 220 (1983)] did not provide enablement for producing the virus in vitro. However, it was discovered by workers in this laboratory that the causative agent of AIDS could be grown in immortalized CD-4 positive cell lines to provide a reliable source of the virus and viral products. The use of these products as diagnostic tools is disclosed in U.S. Pat. No. 4,520,113, which is incorporated herein by reference.

A method of cloning human T-cell leukemia-lymphoma virus (HTLV), a transforming virus which lacks both the variability and cytopathic properties of HIV, is taught in Manzari, et al., [Proc. Natl. Acad. Sci., Vol. 80, pages 1574-1577 (1983)]. There is no teaching of how to clone a highly cytopathic virus of such diverse genomic structure as the HIV. To obtain a virus for cloning, it was necessary to have an infected, immortalized cell line from which to extract the virus. U.S. Pat. No. 4,652,599 to Gallo, et al. teaches such cell lines.

DESCRIPTION OF THE FIGURES

FIG. 1 is a Southern blot analysis of unintegrated DNA of HIV. No viral sequences could be detected in the undigested DNA after 4 hours. However, a major species of viral DNA of approximately 10 kb length was present in the 10, 15, 24 and 48 hour harvest representing the linear unintegrated form of the virus. A representative Southern blot of the 15 hour harvest digested with several restriction enzymes is shown in this figure. Methods: 8×10⁸fresh uninfected H9 cells were infected with concentrated supernatant from cell line H9/HTLV-III (H9/HIV) containing 4×10¹¹particles of HIV. Infected cells were divided into five Roller bottles and harvested after 4, 10, 15, 24 and 48 hours. Low molecular weight DNA was prepared using the Hirt fractionation procedure and 30 g of undigested and digested DNA were separated on a 0.8% agarose gel, transferred to nitrocellulose paper and hybridized to a HIV cDNA probe for 24 hours at 37° C. in 1×SSC, 40% formamide and 10% Dextran sulfate. cDNA was synthesized from poly(A) selected RNA prepared from doubly banded HIV virus in the presence of oligo(dT) primers. Filters were washed at 1×SSC at 65° C.

FIG. 2 is a restriction endonuclease map of two closely related HIV variants cloned from unintegrated viral DNA. Three recombinant clones (λBH10, λBH5 and λBH8) were analyzed and their inserts (9 Kb, 5.5 Kb and 3.5 Kb, respectively) were mapped with the indicated enzymes. They represent two variant forms of HIV differing in three enzyme sites which are depicted in bold letters and by an asterisk. As SstI cuts the LTR of the HIV the three clones represent two full-length genomes with one LTR. A schematic map of this viral genome is shown at the bottom of the figure, although the total length of the LTR is approximate.

FIG. 3 demonstrates HIV viral sequences in the infected cell line H9/HIV. Both variant forms of HIV were detected as integrated provirus as well as unintegrated viral DNA in the infected cell line. However, no viral sequences were found in uninfected H9 cells, uninfected HT cells nor in normal human thymus (NT).

FIG. 4 shows a sequence homology of HIV to related retroviral members of the HTLV family. A schematic restriction map of HTLV-I, HTLV-Ib and HTLV-II is drawn below indicating the length and the location of the generated fragments in respect to the corresponding genomic regions.

FIG. 5 represents the entire nucleotide sequence of the molecular clone BH5 (ATCC #40126), which is approximately one half of a cloned genomic sequence for an HIV strain on deposit with the American Type Culture Collection.

FIG. 6 represents the entire nucleotide sequence of the molecular clone BH8 (ATCC #40127), which is approximately the second half of the genomic sequence for the HIV strain noted in FIG. 5.

FIG. 7 represents the entire nucleotide sequence of the molecular clone BH10 (ATCC #40125), which is approximately the entire cloned genomic sequence of an HIV strain, different from the strain noted in FIGS. 5 and 6, on deposit with the American Type Culture Collection.

FIG. 8 shows restriction endonuclease maps of four closely related clones of HIV. λHXB-2 and λHXB-3 represent full-length integrated proviral forms of HIV obtained from the λ phage library of H9/HIV DNA (Example 3). These clones contain the complete provirus (thin lines) including two LTR regions plus flanking cellular sequences (heavy lines). The LTR regions are known to contain the three restriction enzyme sites Bgl II, Sst I, and Hind III, as shown, but their overall lengths are estimated. Clones λBH-10 and λBH-5/λBH-8 are shown here for comparison with λHXB-2 and λHXB-3 and with Southern blots of genomic DNA from other HTLV-III containing cells. It should be noted that λBH-5/λBH-8 consists of two separate clones Sst I fragments (λBH-5 and λBH-8) which together constitute one HIV genomic equivalent but which are not necessarily derived from the same viral molecule. Also, because λBH-10 and λBH-5 were cloned with the restriction enzyme Sst I, they lack 5′ LTR sequences as shown. Other differences in the restriction maps between these HIV clones are indicated by bold letters and asterisks, with λBH-10 being used as a reference.

FIG. 9 shows the construction of a plasmid containing sequences of the HIV genome. A 12.7-kb XbaI fragment derived from HXB-2, a molecular clone containing about 10 kb of HIV proviral sequences, was inserted into the XbaI site in the polylinker of plasmid pSP62 to produce the plasmid clone pHXB-2D. This plasmid construct was then transfected into DH-1 bacteria and used in protoplast fusion experiments. The thin horizontal line represents HIV and the solid boxes represent flanking cellular sequences.

DETAILED DESCRIPTION OF THE INVENTION

Clones are prepared using both unintegrated DNA and integrated DNA proviral DNA. The clones of integrated DNA and unintegrated DNA are similar, but are distinguishable by differences in several restriction cleavage sites. From FIG. 8, it is shown λBH-10 and λBH-5/λBH-8 are incomplete viral clones which lack a short SstI-SstI segment of approximately 190 base pairs in the 5′ LTR-leader sequence as a consequence of use of Sst I in their cloning. The λHXB-2 and λHXB-3 clones contain full-length integrated provirus [˜10 kilobases (kb)] with cellular flanking sequences.

Plasmids are constructed using λHXB-2 to produce pHXB-2D A 12.7 kb XbaI fragment derived from pHXB-2D was inserted into the XbaI site in the polylinker of plasmid pSP62 to provide a plasmid suitable for transfection into the DH-1 bacteria.

Preparation of Clones λBH10, λBH5, and λBH8
Example 1

Concentrated virus from the H9/HTLV-III cell line as used to infect fresh uninfected H9 cells at a multiplicity of 50 viral particles per cell and cultures were collected after 4, 10, 15, 24 and 48 hours. Extrachromosomal DNA was extracted according to the procedure of Hirt [Hirt, R., J. Molec. Biol. 26: 365-367 (1967)] and assayed for its content of unintegrated viral DNA using HIV cDNA as a probe. The synthesis of this cDNA was primed with oligo(dT) and reverse-transcribed from poly(A)-containing RNA of virions that had been banded twice on sucrose density gradients [Arya, et al., Science 225: 927-930 (1984)]. Unintegrated linear viral DNA was first detected after 10 h and was also present at the subsequent time points. (FIG. 1 shows a Southern blot of the 15-h sampling.) A band of ˜10 kilobases (kb) in the undigested DNA represents the linear form of unintegrated HIV. No closed or nicked circular DNA could be detected at 10, 15 or 24 hours, but both forms were evident in small amounts at 48 hours (data not shown). The viral genome was not cleaved by XbaI, whereas SstI generated three predominant bands of 9, 5.5 and 3.5 kb (FIG. 1). These bands represent the genomes of two forms of HIV, both cut by SstI in or near the long terminal repeat (LTR), and one having an additional SstI site in the middle of its genome. The other enzymes generate a more complex pattern of restriction fragments.

FIG. 2 shows the restriction map of three clones, designated λBH10, λBH5 and λBH8, which correspond in size to the three SstI fragments shown in FIG. 1. Comparison of these maps suggests that λBH5 plus λBH8 constitute one HIV genome, and BH10 another. The two viral forms differ in 3 of 21 mapped enzymes sites, including the internal SstI site. As expected, the phage inserts of λBH5 and λBH8 hybridize in high-stringency conditions (T_m-25° C.) to λBH10 but not to each other, as analyzed by Southern blot hybridization and electron microscopic hetero-duplex analysis (data not shown). To determine the orientation of the three clones, we used as a probe a cDNA clone (C15) containing U3 and R sequences. C15 hybridized strongly to the 0.5 kb BglII fragment of λBH10 and λBH8, orienting this side 3′. Assuming that SstI cuts only once in the vicinity of the HIV LTR, the clones λBH10 and λBH5/λBH8 represent two complete genomic equivalents of the linear unintegrated form of HIV that vary in three restriction enzyme sites.

Methods: Low molecular weight DNA combined from the 15 and 24 hour harvest was fractionated on a 10-40% sucrose gradient. Aliquots of the fractions were electrophoresed on a 0.5% agarose gel, transferred to nitrocellulose paper and hybridized to HIV cDNA under conditions described in FIG. 1. Fractions which contained the unintegrated linear HIV genome shown by hybridization were pooled, the DNA was subsequently digested with SstI and ligated to phosphatase treated SstI arms of λgtWes. λB. After in vitro packaging, recombinant phages were screened for viral sequences with HIV cDNA.

Example 2

The presence of two variant forms of HIV in the original cell line was demonstrated by hybridizing the radiolabelled insert of λBH10 to a Southern blot of H9/HIV genomic DNA digested with several restriction enzymes (FIG. 3); both forms were detected using SstI, which generated the expected three bands of 9, 5.5 and 3.5 kb. XbaI, which does not cut the provirus, generated a high-molecular weight smear representing polyclonal integration of the provirus, plus a band of ˜10 kb. This 10-kb band was also detected in undigested H9/HIV DNA (not shown), indicating that it represents unintegrated viral DNA. The presence of unintegrated viral DNA also explains the 4- and 4.5-kb EcoRI fragments seen in both the Hirt and total cellular DNA preparations (FIGS. 1, 3). Both BglII and HindIII cut within the LTR and generate the expected internal bands. Several faint bands in addition to the expected internal bands generated by HindIII digestion, represent either defective proviruses or other variant forms of HIV present in low copy number.

Method: 10 μg of high molecular weight DNA were digested with restriction enzymes as indicated and hybridized to nick translated phage insert from BH10 under the same conditions as described in FIG. 1.

For comparison, sub-clones of full length genomes of a prototype HTLV-I, HTLV-Ib, HTLV and GaLV (Seato strain) were digested with the following enzymes, PstI plus SstI (HTLV-I and HTLV-Ib), BamHI plus SmaI (HTLV-II) and Hind III plus SmaI plus XhoI (GaLV). Four replicate filters were prepared and hybridized for 36 hours under low stringency (8×SSC, 20% formamide, 10% Dextran sulfate at 37° C.) to nick translated insert of λBH10. Filters were then washed in 1×SSC at different temperatures, 22° C. (Tm−70° C.) filter 1, 37° C. (Tm−56° C.) filter 2, 50° C. (Tm−42° C.) filter 3 and 65° C. (Tm−28° C.).

FIG. 4 shows a sequence homology between HIV and other related retroviruses. Hybridization of HIV with the related HTLV family could be detected where no hybridization to GaLV was seen.

Preparation of Clones Containing Integrated Proviral DNA
Example 3

The HIV is used to infect H9 cells in accord with the method of Example 1. Preliminary analyses of Southern digests of H9/HIV DNA reveals that the virus is present in this cell line both as unintegrated DNA and as proviral DNA integrated into the cellular genome at multiple different sites. Since the HIV provirus lacks Xba I restriction sites, a genomic library was constructed by using Xba I-digested H9/HIV DNA, and this was screened with an HIV cDNA probe to obtain molecular clones of full-length integrated provirus with flanking cellular sequences. Fourteen such clones were obtained from an enriched library of 10⁶recombinant phage, and two of these were plaque-purified and characterized. (See FIG. 8.)

To show that the restriction enzyme cleavage sites depicted in FIG. 8 for clones λHXB-2 and λHXB-3 are actually present in the viral DNA of HIV-infected H9 cells, DNA was digested from the H9/HIV cell line with various restriction enzymes and analyzed it by the Southern blot technique. The restriction fragments for Sst I, Eco RI, Hind III, Pst I, Bam H1, and BglII predicted from the restriction maps of λHXB-2 and λHXB-3 (FIG. 8) are shown to be present in the Southern blots of HIV infected cellular DNA.

Example 4

To determine whether the HIV genome contains sequences homologous to normal human DNA, the viral insert of λHXB-2 (5.5 kb and 3.5 kb Sst I-Sst I fragments) was isolated, nick translated, and used to probe HIV-infected and uninfected cellular DNA. Under standard conditions of hybridization [washing conditions: 1×SSC (standard saline citrate), 65° C.; annealing temperature T_m−27 C], this probe hybridizes to DNA from H9/HIV cells as well as other HIV-infected cells, but not to DNA from uninfected H9 cells, uninfected HT cells (the parent cell line from which H9 as cloned), or normal human tissues (data not shown). This finding is in agreement with previous results in which the unintegrated (replicative intermediate) form of HIV was used as probe and demonstrates that HIV, like HTLV-1 and HTLV-II, is an exogenous retrovirus lacking nucleic acid sequences derived from human DNA.

Example 5

A 12.7 kb XbaI fragment derived from λHXB-2 is inserted into the polylinker of plasmid pSP62 to produce plasmid clone pHXB-2D (FIG. 9). The pHXB-2D is transfected into DH-1 bacteria for use in protoplast fusion experiments.

Example 6

Kinetics of cell growth and reverse transcriptase activity in cord blood mononuclear cell cultures following protoplast fusion: Mononuclear cells were prepared from cord blood samples using Ficoll Triosil and cultured for 5 days in media containing PHA. These cells were then fused with bacterial protoplasts carrying the plasmid pHXB-2D, pSV2neo or pCH-1gpt and maintained in culture at a density of 5×10⁵cells ml⁻¹by addition of RPMI-1640 medium containing 20% fetal calf serum, 10% T-cell growth factor (inter-leukin-2) and antibiotics. Three parallel fusions using cells from different individuals were established for each plasmid. Spent medium removed from two cultures at 5, 11, 14 and 18 days after fusion was concentrated 10-fold and assayed for the presence of reverse transcriptase using standard techniques. The activity detected in each of the culture supernatants is expressed as the amount of ³H-labeled deoxyribonucleotide monophosphate (³H-dTMP) incorporated (in pmol per 0.3-ml sample) using dT₁₅·(rA)_nas the template primer.

The growth of all cultures was comparable for the first 14 days after protoplast fusion. By day 18, however, the number of viable cells in cultures transfected with pHXB-2D had fallen dramatically: there was a 10-fold and a 100-fold reduction between days 18 and 21 and 18 and 32, respectively. Cultures transfected with either pSV2neo or pCH-1gpt showed only a 4-5-fold reduction over the same time period. When supernatant from the cultures was assayed for the presence of reverse transcriptase, activity was detected exclusively in cultures transfected with pHXB-2D. These data suggest that replicating virus was present in cultures 11-18 days after fusion with pHXB-2D protoplasts.

Example 7

Expression of the HIV gag-related proteins p15 and p24 by transfected cells was demonstrated using specific monoclonal antibodies. Maximum expression was observed 18 days after transfection, when 4-11% and 5-9% of cells were reactive with antibody to p15 and p24, respectively. Virus particles were detected by electron microscopy in all cultures 14-18 days after transfection with pHXB-2D. The particles contained condensed, truncated cores, which are characteristic of HIV particles.

Example 8

In time-course experiments, DNA isolated from a single culture 6, 11, 14, 18 and 31 days after transfection with pHXB-2D, was digested with BamHI and analyzed for HIV sequences. Six days after transfection, an 8.6-kb DNA fragment was detected as a faint band; 18 days after transfection it was possible to detect a 1.5-kb DNA fragment in addition to the 8.6-kb fragment. The total amount of unintegrated virus in the cultures appeared to increase, as suggested by the increase in intensity of these bands with time; this is evidence that cells originally transfected with pHXB-2D are able to produce fully infectious virus which is then transmitted within the culture.

No HIV viral sequences were detected 31 days after transfection; at this point the culture may have contained only cells which failed to be infected by HIV. This result is again consistent with the transfected DNA exerting a cytopathic effect on T cells. The finding that, at any stage, only a minor population of the transfected cells are apparently infected by the virus (<15% express viral proteins) suggests that the cytopathic effects may not result solely from direct viral infection and that secreted factors and/or other cell-to-cell interactions may play a part in the cytopathic phenomenon.

The biological materials relating to the invention have been deposited at the American Type Culture Collection, Rockville, Md., under the following accession numbers:

λBH-10
40125 (FIG. 7)

λBH-5
40126 (FIG. 5 )

λBH-8
40127 (FIG. 6)

λ-HXB₂
40231

λ-HXB₃
40232

pHXB3
67081

pHXB-2D
67082

X10-1 (Ecoli DH-1)
67083

Upon issuance of a patent on the present invention, this deposit will continue to be viably maintained for 30 years and made available to the public without restriction, of course, consistent with the provisions of the law.

Examples of useful products are now described:

1. Viral particles and proteins may be extracted from both supernatants and whole cells.

2. Supernatant material may be purified for use in test kits for immunoblotting and immunoadsorbent tests.

3. Monoclonal antibodies may be produced which react against HIV antigens.

4. The antigens may be used as immunogens in vaccine development.

Both antibodies and antigens can be used in diagnostic kits. Both antibodies and antigens can be provided as compositions. Particularly preferred compositions of matter are solid supports having antigens of the invention adhering thereto for use in identifying antibodies to HIV proteins for use in Enzyme-linked-immunoabsorbent (ELISA) assays.

It is understood that the examples and embodiments described herein are for illustration purposes. Examples are not intended to be viewed as limitations since many obvious modifications are within the scope of one skilled in the art.

TABLE I

CLAIMS SUPPORT CHART

Support in U.S. patent application 06/643,306

Claim
filed on Aug. 22, 1984

61. (new) A method for detecting the presence of a polynucleotide
page 1, lines 28-34. discusses the use of cDNA clones of the invention

comprising a human immunodeficiency virus (HIV) nucleotide sequence in a
to distinguish HTLV III from HTLV I and II.

nucleic acid sample obtained from a physiological sample, which method
p. 3 line 25 to p. 4 line 8 discuss regions of homology and regions of

comprises the steps of:
variability between HTLV III, and HTLV I and II, that can be exploited

(a) combining said nucleic acid sample with a single-stranded
in distinguishing between the different viruses.

nucleic acid probe comprising a sequence of at least about 18 contiguous bases
p. 5, lines 12-14 discusses production of a cDNA library for use in

selected from one of the nucleotide sequences shown in FIGS. 5, 6 or 7 and
analyzing the HIV genome.

complementary to said HIV genomic sequence comprised in said polynucleotide,
p. 5 line 29 - p. 6 line 10 provides support for making probes from HIV

said probe not forming a duplex with HTLV-I and -II nucleic acid sequences under
mRNA.

conditions of stringency for hybridization under which said probe forms a duplex
p. 6, lines 23-26 discusses using probes to assay viral DNA

with said polynucleotide; and
p. 7, lines 18-30 discuss using an λ phage clone in Southern analysis of

(b) determining duplex formation between said probe and nucleic
restriction fragments from HIV DNA.

acid present in said sample.
Statement of Deposit, p. 6.

p. 1 discussion relating to detection of HIV in human sera.

BH10 contains an 18 base BglII-SstI restriction fragment.

FIG. 4 shows that only a fraction of the HTLV-I and -II genomes

hybridize to HTLV-III.

Example 2, p. 8 discusses the use of stringency washes to distinguish

homology between HIV, HTLV I and HTLV II.

62. (new) The method of claim 61 wherein the probe sequence is
p. 3 contains a discussion relating to the presence of gag, pol and env in

complementary to a sequence which is part of the gag, pol or env open reading
HTLV-III.

frame.

63. (new) The method of claim 62 wherein the probe sequence is

complementary to a sequence which is part of the gag open reading frame.

64. (new) The method of claim 62 wherein the probe is complementary to a

sequence which is part of the pol open reading frame.

65. (new) The method of claim 61 wherein the probe comprises RNA.
p. 5 discussion of the use of RNA as probe/probe template.

67. (new) The method of claim 62 wherein the probe comprises RNA.

66. (new) The method of claim 61 wherein the probe comprises DNA.
Support noted for claim 1 refers to DNA probes

68. (new) The method of claim 62 wherein the probe comprises DNA.

69. (new) A method comprising the steps of:
Support noted for claim 61 also applies here.

(a) providing a sample suspected of containing a polynucleotide;
clone BH5 contains a HindIII-XbaI fragment that is 103 bases in

(b) providing a single-stranded nucleic acid of 18-103 bases
length.

comprising a sequence of bases of at least 18 contiguous bases selected from the
p. 3 contains a discussion relating to the presence of gag, pol and env in

gag, env, or pol open reading frames of FIG. 5, 6 or 7 or the complement thereof;
HTLV-III.

and

(c) combining said sample and said single-stranded nucleic acid

under hybridization conditions that (i) permit duplex formation between said single-

stranded nucleic acid and either strand of viral DNA from a lambda bacteriophage

selected from the group consisting of ATCC Accession no. 40143 and 40144, but

(ii) do not permit duplex formation with either HTLV-I or HTLV-II genomic

sequences.

70. (new) A method comprising the steps of:

(a) providing a sample suspected of containing a polynucleotide;

(b) providing a single-stranded nucleic acid of 32-103 bases

comprising a sequence of bases of at least 32 contiguous bases selected from the

gag, env, or pol open reading frames of FIG. 5, 6 or 7 or the complement thereof;

and

(c) combining said sample and said single-stranded nucleic acid

under hybridization conditions that (i) permit duplex formation between said single-

stranded nucleic acid and either strand of viral DNA from a lambda bacteriophage

selected from the group consisting of ATCC Accession no. 40143 and 40144, but

(ii) do not permit duplex formation with either HTLV-I or HTLV-II genomic

sequences.

71. (new) The method of claim 69 or 70 wherein contiguous bases are from
p. 3 contains a discussion relating to the presence of gag, pol and env in

the gag open reading frame or the complement thereof.
HTLV-III.

72. (new) The method of claim 69 or 70 wherein said contiguous bases are

from the env open reading frame or the complement thereof.

73. (new) The method of claim 69 or 70 wherein said contiguous bases are

from the pol open reading frame or the complement thereof.

74. (new) The method of claim 61, 69 or 70 wherein said single-stranded
SstI pg. 2 and FIG. 2;

nucleic acid comprises DNA and wherein said contiguous bases are within a
HindIII pg. 4, and FIG. 2;

restriction fragment produced by cleavage of the nucleic acid presented in FIG. 5,
PstI pg. 2 and FIG. 2

6 or 7 using one or more restriction enzymes selected from the group consisting of
Bgl II pg. 7 and FIG. 2;

SstI, HindIII, PstI, Bgl II, Kpn I, EcoRI, BamHI, HpaI, XhoI, XbaI and SmaI.
Kpn I FIG. 2;

EcoRI Page 7 and FIG. 2;

BamHI Page 2 and FIG. 2;

HpaI Page 2 and FIG. 2;

XhoI Page 2 and FIG. 2;

XbaI Page 7 and FIG. 3; and

SmaI FIG. 2.

75. (new) The method of claim 74 wherein the single-stranded nucleic acid
p. 9, lines 28-32 discusses the use of λBH10 and restriction fragments

probe comprises one of the nucleotide sequences selected from the group consisting
to analyze the HIV genome.

of: [Restriction Fragments supported in Wong-Staal specification.]
p. 6, lines 23-26 discusses using cDNA to detect viral DNA

76. (new) The method of claim 75, wherein the single-stranded nucleic acid
p. 7, lines 18-30 and p. 9 lines 15-26 discuss using an λ phage clone in

is 5′-CTTTAAGACCAATGACTTACAAGGCAGCTGTA -3′.
Southern analysis of restriction fragments from HIV DNA.

32 nucleotide restriction fragment present in BH8.

Nucleotide sequence of claim 76 nucleic acid is a 32 nucleotide KpnI-

BglII restriction fragment from clone BH8

77. (new) A method for detecting the presence of a polynucleotide
Support cited for claim 1 is applicable here.

comprising a human immunodeficiency virus (HIV) nucleotide sequence in a
See also support for claim 76.

nucleic acid sample obtained from a physiological sample, which method

comprises the steps of:

(a) combining said nucleic acid sample with a single-stranded

nucleic acid probe comprising a sequence of at least about 32 contiguous bases

selected from one of the nucleotide sequences shown in FIGS. 5, 6 or 7 and

complementary to said HIV genomic sequence comprised in said polynucleotide,

said probe not forming a duplex with HTLV-I and -II nucleic acid sequences under

conditions of stringency for hybridization under which said probe forms a duplex

with said polynucleotide; and

(b) determining duplex formation between said probe and nucleic

acid present in said sample.

78. (new) The method of claim 61, wherein the single-stranded nucleic acid
18 base BglII-SstI restriction fragment of BH10.

probe is 5′- GATCTGAGCCTGGGAGCT-3′.

79. (new) The method of any of claims 69-73 wherein said single-stranded
Discussion on p. 5 relating to the use of RNA as probe/probe template.

nucleic acid comprises RNA.

80. (new) The method of any of claims 69-73 wherein said single-stranded
p. 1, lines 28-34. discusses the use of cDNA clones of the invention to

nucleic acid comprises DNA.
distinguish HTLV III from HTLV I and II.

81. (new) The method of claim 79 wherein said single-stranded nucleic acid
Original claim 5 discusses radiolabels.

further comprises a label.
FIGS. 1, 3 and 4 show assays using labeled DNA.

82. (new) The method of claim 80 wherein said single-stranded nucleic acid
p5, lines 24-26 discuss labeled probes, and p. 7 lines 18-22 discuss nick

further comprises a label.
translation.

83. (new) The method of claims 69-73, wherein said sample is a human
p. 1 contains a discussion of the use of probes to detect HTLV-III in

sample.
human sera.

84. (new) The method of claim 83, wherein said human sample is blood,

lymph or saliva.

85. (new) The method of claims 84, wherein said sample is blood.

86. (new) A method for detecting the presence of a polynucleotide
page 1, lines 28-34. discusses the use of cDNA clones of the invention

comprising a human immunodeficiency virus (HIV) nucleotide sequence in a
to distinguish HTLV III from HTLV I and II.

nucleic acid sample, the method comprising the steps of:
p. 3 line 25 to p. 4 line 8 discuss regions of homology and regions of

(a) combining said nucleic acid sample with a single-stranded nucleic acid
variability between HTLV III, and HTLV I and II, that can be

probe hybridizing under stringent conditions to an HIV nucleotide sequence present
exploited in distinguishing between the different viruses.

in a nucleic acid deposit selected from the group consisting of H9/HTLV-III cell
p. 5, lines 12-14 discusses production of a cDNA library for

line, CRL 8543; BH10, ATCC #40125; BH8, ATCC #40127; and BH5, ATCC
hybridization analysis of the HIV genome.

#40126, said probe not forming a duplex with HTLV-I and -II nucleic acid
p. 5 line 29 - p. 6 line 10 provides support for making cDNA probes

sequences under conditions of stringency for hybridization that allow said probe to
from HIV mRNA.

form a duplex with said polynucleotide; and
p. 6, lines 23-26 discusses using cDNA probes to assay viral DNA

(b) determining duplex formation between said probe and said nucleic acid
p. 7, lines 18-30 discuss using an λ phage clone in southern analysis of

present in said sample.
restriction fragments from HIV DNA by Southern blot.

Statement of Deposit, p. 6.

Example 2, p. 8 discusses the use of stringency washes to distinguish

homology between HIV, HTLV I and HTLV II.

87. (new) The method of claim 86, wherein the nucleic acid probe is a
p. 5 lines 23-28 discuss hybridizing cDNA sequences to genomic

restriction fragment.
restriction fragments of HIV.

88. (new) The method of claim 86, wherein the probe sequence is
p. 5, lines 12-14 discusses production of a cDNA library for

complementary to a sequence that is part of the gag, pol or env coding regions.
hybridization analysis of the HIV genome.

p. 5 lines 23-28 discuss hybridizing cDNA sequences to genomic

restriction fragments of HIV.

See also, FIG. 4 (restriction map) and p. 3, line 30 to p. 4 line 3.

89. (new) The method of claim 86, wherein the probe comprises DNA.
Support noted for claim 1 refers to DNA probes

90. (new) The method of claim 87, wherein the probe comprises DNA.

91. (new) A method comprising the steps of:
p. 1, lines 28-34. discusses the use of cDNA clones of the invention to

(a) providing a sample suspected of containing a polynucleotide;
distinguish HTLV III from HTLV I and II.

(b) providing a single-stranded HIV cDNA; and,
p. 3 line 25 to p. 4 line 8 discuss regions of homology and regions of

(c) combining said sample and said single-stranded HIV cDNA under
variability between HTLV III, and HTLV I and II, that can be exploited

hybridization conditions that (i) permit duplex formation between said HIV cDNA
in distinguishing between the different viruses.

and either nucleotide strand from a lambda bacteriophage selected from the group
p. 5, lines 12-14 discusses production of a cDNA library for

consisting of λBH10, λBH5 and λBH8, but (ii) do not permit duplex formation
hybridization analysis of the HIV genome.

with either HTLV-I or HTLV-II genomic sequences.
p. 5 line 29 - p. 6 line 10 provides support for making cDNA probes

from HIV mRNA.

p. 9, lines 28-32 discusses the use of the λBH10 clone and HIV

genomic restriction fragments in hybridization studies.

p. 6, lines 23-26 discusses using cDNA probes to assay viral DNA

p. 7, lines 18-30 and p. 9 lines 15-26 discuss using an λ phage clone in

Southern analysis of restriction fragments from HIV DNA.

Statement of Deposit, p. 6.

Example 2, p. 8 discusses the use of stringency washes to distinguish

homology between HIV, HTLV I and HTLV II.

92. (new) The method of claim 91, wherein said single-stranded nucleic
FIGS. 2 and 3 provide restriction maps that would allow one of skill to

acid is an SstI fragment or complement thereof.
identify probes to particular genomic regions.

p. 9, lines 28-32 specifically discusses use probes to analyze restriction

fragments. Also note discussion from p. 5, line 29 to p. 6, line 26

regarding the use of cDNA probes

See also, FIG. 4 and p. 3, line 30 to p. 4 line 3.

93. (new) The method of claim 91 wherein said single-stranded nucleic acid
FIGS. 2 and 3 provide restriction maps that would allow one of skill to

is a HindIII fragment or complement thereof.
identify probes to particular genomic regions.

p. 9, lines 28-32 specifically discusses hybridization analysis using

restriction fragments. Also note discussion from p. 5, line 29 to p. 6,

line 26 regarding the use of cDNA sequences as probes.

See also, FIG. 4 and p. 3, line 30 to p. 4 line 3.

94. (new) The method of claim 91 wherein said single-stranded nucleic acid
FIGS. 2 and 3 provide restriction maps that would allow one of skill to

comprises DNA and hybridizes to a restriction fragment generated by treating an
identify probes to particular genomic regions.

HIV genomic nucleic acid with HindIII and BamHI.
p. 9, lines 28-32 specifically discusses use probes to analyze restriction

fragments. Also note discussion from p. 5, line 29 to p. 6, line 26

regarding the use of cDNA probes

See also, FIG. 4 and p. 3, line 30 to p. 4 line 3.

95. (new) The method of any of claims 91-94 wherein said single-stranded
p. 1, lines 28-34. discusses the use of cDNA clones of the invention to

nucleic acid comprises DNA.
distinguish HTLV III from HTLV I and II.

96. (new) The method of claim 95 wherein said single-stranded nucleic acid
Original claim 5 discusses radiolabels.

further comprises a label.
FIGS. 1, 3 and 4 show assays using labeled DNA.

p5, lines 24-26 discuss labeled probes, and p. 7 lines 18-22 discuss nick

translation.

97. (new) The method of claim 92 wherein said single-stranded nucleic acid
FIGS. 2 and 3 provide restriction maps that would allow one of skill to

comprises DNA and wherein said contiguous bases are within the gag open reading
identify probes to particular genomic regions.

frame.
p. 9, lines 28-32 specifically discusses hybridization analysis using

restriction fragments. Also note discussion from p. 5, line 29 to p. 6,

line 26 regarding the use of cDNA sequences as probes.

See also, FIG. 4 and p. 3, line 30 to p. 4 line 3.

98. (new) The method of claim 97 wherein said single-stranded nucleic acid
Original claim 5 discusses radiolabels.

further comprises a label.
FIGS. 1, 3 and 4 show assays using labeled DNA.

p5, lines 24-26 discuss labeled probes, and p. 7 lines 18-22 discuss nick

translation.

99. (new) A method for detecting the presence of a polynucleotide
page 1, lines 28-34. discusses the use of cDNA clones of the invention

comprising a human immunodeficiency virus (HIV) genomic sequence in a nucleic
to distinguish HTLV III from HTLV I and II.

acid sample obtained from a physiological sample, which method comprises the
p. 3 line 25 to p. 4 line 8 discuss regions of homology and regions of

steps of:
variability between HTLV III, and HTLV I and II, that can be exploited

(a) combining said nucleic acid sample with a single-stranded
in distinguishing between the different viruses.

nucleic acid probe comprising a sequence of at least about 20 contiguous bases
p. 5, lines 12-14 discusses production of a cDNA library for use in

selected from the nucleotide sequences shown in FIGS. 5-7 and complementary to
hybridization studies of the HIV genome.

said HIV genomic sequence comprised in said polynucleotide, said probe not
p. 5 line 29 - p. 6 line 10 provides support for making cDNA probes

forming a duplex with HTLV-I and -II nucleic acid sequences under conditions of
from HIV mRNA.

stringency for hybridization under which said probe forms a duplex with said
p. 6, lines 23-26 discusses using cDNA sequences for use in

polynucleotide; and
hybridization studies of the HIV genome.

(b) determining duplex formation between said probe and nucleic
p. 7, lines 18-30 discuss using an λ phage clone in Southern analysis of

acid present in said sample.
restriction fragments from HIV DNA.

Statement of Deposit, p. 6.

p. 1 discussion relating to detection of HIV in human sera.

BH10 contains an 18 base BglII-SstI restriction fragment.

100. (new) The method of claim 99 wherein the probe sequence is
p. 3 contains a discussion relating to the presence of gag, pol and env in

complementary to a sequence which is part of the gag, pol or env open reading
HTLV-III.

frame.

101. (new) The method of claim 100 wherein the probe sequence is

complementary to a sequence which is part of the gag open reading frame.

102. (new) The method of claim 100 wherein the probe is complementary to

a sequence which is part of the pol open reading frame.

103. (new) The method of claim 99 wherein the probe comprises RNA.
p. 5 discussion of the use of RNA as probe/probe template.

105. (new) The method of claim 100 wherein the probe comprises RNA.

104. (new) The method of claim 99 wherein the probe comprises DNA.
Support noted for claim 1 refers to DNA probes

106. (new) The method of claim 100 wherein the probe comprises DNA.

107. (new) A method comprising the steps of:
Support noted for claim 61 also applies here.

(a) providing a sample suspected of containing a polynucleotide;
p. 3 contains a discussion relating to the presence of gag, pol and env in

(b) providing a single-stranded nucleic acid of 20-100 bases
HTLV-III.

comprising a sequence of bases of at least 20 contiguous bases selected from the

gag, env, or pol open reading frames; and

(c) combining said sample and said single-stranded nucleic acid

under hybridization conditions that (i) permit duplex formation between said single-

stranded nucleic acid and either strand of viral DNA from a lambda bacteriophage

selected from the group consisting of ATCC Accession no. 40143 and 40144, but

(ii) do not permit duplex formation with either HTLV-I or HTLV-II genomic

sequences.

108. (new) The method of any of claims 107 wherein said single-stranded
p. 5 discussion of the use of RNA as probe/probe template.

nucleic acid comprises RNA.
Support noted for claim 1 refers to DNA probes

109. (new) The method of any of claims 107 wherein said single-stranded

nucleic acid comprises DNA.

110. (new) The method of claim 108 wherein said single-stranded nucleic
Original claim 5 discusses radiolabels.

acid further comprises a label.
FIGS. 1, 3 and 4 show assays using labeled DNA.

111. (new) The method of claim 109 wherein said single-stranded nucleic
p5, lines 24-26 discuss labeled probes, and p. 7 lines 18-22 discuss nick

acid further comprises a label.
translation.

112. (new) The method of claim 108 wherein said single-stranded nucleic
The paragraph spanning pages 5 and 6 discusses chemically

acid is chemically synthesized at least in part.
synthesizing DNA using NaOH, an RNA template, and restriction

113. (new) The method of claim 109 wherein said single-stranded nucleic
enzymes.

acid is chemically synthesized at least in part.

114. (new) The method of claim 110 wherein said single-stranded nucleic

acid is chemically synthesized at least in part.

115. (new) The method of claim 111 wherein said single-stranded nucleic

acid is chemically synthesized at least in part.

116. (new) The method of claims 99 or 101 wherein said sample is a human
p. 1 contains a discussion of the use of probes to detect HTLV-III in

sample.
human sera.

117. (new) The method of claim 116 wherein said human sample is blood,

lymph or saliva.

118. (new) The method of claims 99 or 101 wherein said sample is blood,

lymph or saliva.

TABLE II

(BH 5 and 8 v. LUCIW)

89.8% identity

10 20 30 40 50

BH 8 -TGGAAGGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATCCACCAC

:::::::::::::: :::::: :::::::::: :::::::::::::::::: :::::

Licuw, CTGGAAGGGCTAATTTGGTCCCAAAGAAGACAAGAGATCCTTGATCTGTGGATCTACCAC

10 20 30 40 50 60

60 70 80 90 100 110

BH 8 ACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGAGTCAGATATCCA

::::::::::::::::::::::::::::: ::::::::::::::::: :::::::::::

Licuw, ACACAAGGCTACTTCCCTGATTGGCAGAATTACACACCAGGGCCAGGGATCAGATATCCA

70 80 90 100 110 120

120 130 140 150 160 170

BH 8 CTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGAGAAGTAAGAAGAAGCC

::::::::::::::::::: :::::::::::::::::::::::::::: :::::: :::

Licuw, CTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTTGAGCCAGAGAAGGTAGAAGAGGCC

130 140 150 160 170 180

180 190 200 210 220 230

BH 8 AATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATTGATGACCCG

::: :::::::::::: :::::::::::::::: ::::::::::::: :: :: ::: ::

Licuw, AATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCTGCATGGGATGGAGGACGCG

190 200 210 220 230 240

240 250 260 270 280 290

BH 8 GAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACATGGCCCGA

:::: ::::::::::: :::::::::::::::: ::::::::::::::::::::::::

Licuw, GAGAAAGAAGTGTTAGTGTGGAGGTTTGACAGCAAACTAGCATTTCATCACATGGCCCGA

250 260 270 280 290 300

300 310 320 330 340 350

BH 8 GAGCTGCATCCGGAGTACTTCAAGAACTGCTGACATCGAGCTTGCTACAAGGGACTTTCC

::::::::::::::::::: ::: :::::::::::::::::: ::::::::::::::::

Licuw, GAGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAGGGACTTTCC

310 320 330 340 350 360

360 370 380 390 400 410

BH 8 GCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGA

:::::::::::::::::::::::::::::::::::::::::::::::::: ::::::::

Licuw, GCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGT-CCCTCAGA

370 380 390 400 410

420 430 440 450 460 470

BH 8 TCCTGCATATAAGCAG-CTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCT

: :::::::::::::: :::::::::::::::::::::::::::::::::::::::::::

Licuw, TGCTGCATATAAGCAGACTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCT

420 430 440 450 460 470

480 490

BH 8 GAGCCTGGGAGCTC----------------------------------------------

::::::::::::::

Licuw, GAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGC

480 490 500 510 520 530

-------------------------------------------------------------------

Licuw, CTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCC

540 550 560 570 580 590

-------------------------------------------------------------------

Licuw, TCAGACCCTTTTAGTCAGTGTGGAAAAATCTCTAGCAGTGGCGCCCGAACAGGGACGCGA

600 610 620 630 640 650

500 510 520 530

BH 5 --------------------GAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCA

::::::::::::::::::::::::::::::::::::::::

Licuw, AAGCGAAAGTAGAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCA

660 670 680 690 700 710

540 550 560 570 580 590

BH 5 CGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCT

: ::::::::::::::::::::::::::::::::::::: ::::::::::::::::::

Licuw, CAGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAT--TTTTGACTAGCGGAGGCT

720 730 740 750 760 770

600 610 620 630 640 650

BH 5 AGAAGGAGAGAGA--TGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGAT

::::::::::::: :::::::::::::::: :::::::::::::::::::::::: ::

Licuw, AGAAGGAGAGAGAGATGGGTGCGAGAGCGTCGGTATTAAGCGGGGGAGAATTAGATAAAT

780 790 800 810 820 830

660 670 680 690 700 710

BH 5 GGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTAT

::::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::

Licuw, GGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAGTTAAAACATATAGTAT

840 850 860 870 880 890

720 730 740 750 760 770

BH 5 GGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAG

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, GGGCAAGCAGGGAGCTAGAACGATTCGCAGTCAATCCTGGCCTGTTAGAAACATCAGAAG

900 910 920 930 940 950

780 790 800 810 820 830

BH 5 GCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTA

:::: ::::::::: ::::::::::::: :::::::::::::::::::::::::::::::

Licuw, GCTGCAGACAAATATTGGGACAGCTACAGCCATCCCTTCAGACAGGATCAGAAGAACTTA

960 970 980 990 1000 1010

840 850 860 870 880 890

BH 5 GATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAG

::::::::::::::::::::::::::::::::::::: :::::::::::::: ::::::

Licuw, GATCATTATATAATACAGTAGCAACCCTCTATTGTGTACATCAAAGGATAGATGTAAAAG

1020 1030 1040 1050 1060 1070

900 910 920 930 940 950

BH 5 ACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCAC

::::::::::::::::::: ::::::::::::::::::::::::::::::::::: ::::

Licuw, ACACCAAGGAAGCTTTAGAGAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAGGCAC

1080 1090 1100 1110 1120 1130

960 970 980 990 1000

BH 5 AGCAAGCAGCAGCTGA------CACAGGACACAGCAGTCAGGTCAGCCAAAATTACCCTA

::::::::::::::: ::::::::::::::: ::::::::::::::::::::::

Licuw, AGCAAGCAGCAGCTGCAGCTGGCACAGGAAACAGCAGCCAGGTCAGCCAAAATTACCCTA

1140 1150 1160 1170 1180 1190

1010 1020 1030 1040 1050 1060

BH 5 TAGTGCAGAACATCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATG

::::::::::: : ::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAGTGCAGAACCTACAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATG

1200 1210 1220 1230 1240 1250

1070 1080 1090 1100 1110 1120

BH 5 CATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTAATACCCATGTTTTCAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, CATGGGTAAAAGTAGTAGAAGAAAAGGCTTTCAGCCCAGAAGTAATACCCATGTTTTCAG

1260 1270 1280 1290 1300 1310

1130 1140 1150 1160 1170 1180

BH 5 CATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGAC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGAC

1320 1330 1340 1350 1360 1370

1190 1200 1210 1220 1230 1240

BH 5 ATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGAATGGGATA

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, ATCAAGCAGCCATGCAAATGTTAAAAGAGACTATCAATGAGGAAGCTGCAGAATGGGATA

1380 1390 1400 1410 1420 1430

1250 1260 1270 1280 1290 1300

BH 5 GAGTGCATCCAGTGCATGCAGGGCCTATCGCACCAGGCCAGATGAGAGAACCAAGGGGAA

:::::::::::::::::::::::::::: ::::::::::: :::::::::::::::::::

Licuw, GAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAAATGAGAGAACCAAGGGGAA

1440 1450 1460 1470 1480 1490

1310 1320 1330 1340 1350 1360

BH 5 GTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATC

1500 1510 1520 1530 1540 1550

1370 1380 1390 1400 1410 1420

BH 5 CACCTATCCCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, CACCTATCCCAGTAGGAGAAATCTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG

1560 1570 1580 1590 1600 1610

1430 1440 1450 1460 1470 1480

BH 5 TAAGGATGTATAGTCCTACCAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTA

:::: :::::::: ::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTA

1620 1630 1640 1650 1660 1670

1490 1500 1510 1520 1530 1540

BH 5 GAGACTATGTAGACCGGTTCTATAAAACTCTAAGAGCCGAGCAAGCTTCACAGGAAGTAA

:::: ::::::::::::::::::::::::::::::::::: :::::::::::::: ::::

Licuw, GAGATTATGTAGACCGGTTCTATAAAACTCTAAGAGCCGAACAAGCTTCACAGGATGTAA

1680 1690 1700 1710 1720 1730

1550 1560 1570 1580 1590 1600

BH 5 AAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTT

::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::

Licuw, AAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCAAACCCAGATTGTAAGACTATTT

1740 1750 1760 1770 1780 1790

1610 1620 1630 1640 1650 1660

BH 5 TAAAAGCATTGGGACCAGCAGCTACTCTAGAAGAAATGATGACAGCATGTCAGGGAGTGG

::::::::::::::::::::::::: ::::::::::::::::::::::::::::::::::

Licuw, TAAAAGCATTGGGACCAGCAGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTGG

1800 1810 1820 1830 1840 1850

1670 1680 1690 1700 1710 1720

BH 5 GAGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCAA

: ::::::::::::::::::::::::::::::::::: :::::::::::::::::: ::

Licuw, GGGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCCATGAGCCAAGTAACAAATCCAG

1860 1870 1880 1890 1900 1910

1730 1740 1750 1760 1770 1780

BH 5 CTACCATAATGATGCAAAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCA

::: :::::::::::: :::::::::::::::::::::::::::: ::::::::::::::

Licuw, CTAACATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCA

1920 1930 1940 1950 1960 1970

1790 1800 1810 1820 1830 1840

BH 5 ATTGTGGCAAAGAAGGGCACATAGCAAGAAATTGCAAGGCCCCTAGAAAAAGAGGCTGTT

:::::::::::::::: :::::::: : :::::::: ::::::::: :::: ::: :::

Licuw, ATTGTGGCAAAGAAGG-CACATAGCCAAAAATTGCAGGGCCCCTAGGAAAA-AGG--GTT

1980 1990 2000 2010 2020 2030

1850 1860 1870 1880 1890 1900

BH 5 GGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTT

: : ::::::: :::::::::::::::::::::::: ::::::::::::::::::::::

Licuw, TGGAGTGTGGAAGGGAAGGACACCAAATGAAAGATTGCACTGAGAGACAGGCTAATTTTT

2040 2050 2060 2070 2080 2090

1910 1920 1930 1940 1950 1960

BH 5 TAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAG

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAG

2100 2110 2120 2130 2140 2150

1970 1980 1990 2000 2010 2020

BH 5 AGCCAACAGCCCCACCATTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGA

::::::::::::::::: :::::::

Licuw, AGCCAACAGCCCCACCA------------------------------------GAAGAGA

2160 2170

2030 2040 2050 2060 2070 2080

BH 5 GCTTCAGGTCTGGGGTAGAGACAACAACTCCCTCTCAGAAGCAGGAGCCGATAGACAAGG

::::::::: ::::: :::: ::::::::::::::::::::::::::::::::::::::

Licuw, GCTTCAGGTTTGGGGAGGAGAAAACAACTCCCTCTCAGAAGCAGGAGCCGATAGACAAGG

2180 2190 2200 2210 2220 2230

2090 2100 2110 2120 2130 2140

BH 5 AACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATAAA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATTAA

2240 2250 2260 2270 2280 2290

2150 2160 2170 2180 2190 2200

BH 5 G-ATAGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAG

: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAG

2300 2310 2320 2330 2340 2350

2210 2220 2230 2240 2250 2260

BH 5 AAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTA

::::::::: ::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, AAGAAATGAATTTGCCAGGAAAATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTA

2360 2370 2380 2390 2400 2410

2270 2280 2290 2300 2310 2320

BH 5 TCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTA

:::::::::::::::: :::::::::: ::::::::::::::::::::::::::::::

Licuw, TCAAAGTAAGACAGTACGATCAGATACCTGTAGAAATCTGTGGACATAAAGCTATAGGTA

2420 2430 2440 2450 2460 2470

2330 2340 2350 2360 2370 2380

BH 5 CAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTG

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTG

2480 2490 2500 2510 2520 2530

2390 2400 2410 2420 2430 2440

BH 5 GTTGCACTTTAAATTTTCCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAAGCCAG

:::: ::::::::::: :::::::::::::::::::::::::::::::::::::::::::

Licuw, GTTGTACTTTAAATTTCCCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAAGCCAG

2540 2550 2560 2570 2580 2590

2450 2460 2470 2480 2490 2500

BH 5 GAATGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, GAATGGATGGCCCAAAAGTTAAGCAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAG

2600 2610 2620 2630 2640 2650

2510 2520 2530 2540 2550 2560

BH 5 TAGAAATTTGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATC

:::: :: ::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAGAGATATGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATC

2660 2670 2680 2690 2700 2710

2570 2580 2590 2600 2610 2620

BH 5 CATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAG

:::::::::::::::::::::: ::::::::::::::::::::::::::::::::: :::

Licuw, CATACAATACTCCAGTATTTGCTATAAAGAAAAAAGACAGTACTAAATGGAGAAAACTAG

2720 2730 2740 2750 2760 2770

2630 2640 2650 2660 2670 2680

BH 5 TAGATTTCAGAGAACTTAATAGGAGAACTCAAGACTTCTGGGAAGTTCAATTGGGAATAC

::::::::::::::::::::: :::::::::::::::::::::::::: :: :::::::

Licuw, TAGATTTCAGAGAACTTAATAAAAGAACTCAAGACTTCTGGGAAGTTCAGTTAGGAATAC

2780 2790 2800 2810 2820 2830

2690 2700 2710 2720 2730 2740

BH 5 CACATCCCGCAGGGTTAAAAAA-GAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCA

:::: ::::::::::::::::: ::::::::::::::::::: :::::::::::::::::

Licuw, CACA-CCCGCAGGGTTAAAAAAAGAAAAAATCAGTAACAGTATTGGATGTGGGTGATGCA

2840 2850 2860 2870 2880 2890

2750 2760 2770 2780 2790 2800

BH 5 TATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGT

:: :::::::::::::::::: ::::::: :: :::::::::::::::::::::::::::

Licuw, TACTTTTCAGTTCCCTTAGATAAAGACTTTAGAAAGTATACTGCATTTACCATACCTAGT

2900 2910 2920 2930 2940 2950

2810 2820 2830 2840 2850 2860

BH 5 ATAAATAATGAGACACCAGGGATTAGATATCAGTACAATGTG-CTTCCACAGGGATGGAA

::::: :::::::::::::::::::::::::::::::::::: :: ::::::::::::::

Licuw, ATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGGCTGCCACAGGGATGGAA

2960 2970 2980 2990 3000 3010

2870 2880 2890 2900 2910 2920

BH 5 AGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACA

3020 3030 3040 3050 3060 3070

2930 2940 2950 2960 2970 2980

BH 5 AAATCCAGACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGA

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GAATCCAGACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGA

3080 3090 3100 3110 3120 3130

2990 3000 3010 3020 3030 3040

BH 5 AATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGATT

:::::::::::::::::::::::::::::: :::::::: ::::::::::::::::::::

Licuw, AATAGGGCAGCATAGAACAAAAATAGAGGAACTGAGACAGCATCTGTTGAGGTGGGGATT

3140 3150 3160 3170 3180 3190

3050 3060 3070 3080 3090 3100

BH 5 TACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT

3200 3210 3220 3230 3240 3250

3110 3120 3130 3140 3150 3160

BH 5 CCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGT

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, CCATCCTGATAAATGGACAGTACAGCCTATAATGCTGCCAGAAAAAGACAGCTGGACTGT

3260 3270 3280 3290 3300 3310

3170 3180 3190 3200 3210 3220

BH 5 CAATGACATACAGAAGTTAGTGGGAAAATTGAATTGGGCAAGTCAGATTTATCCAGGGAT

:::::::::::::::::::::::::::::::::::::::::::::::::::: :::::::

Licuw, CAATGACATACAGAAGTTAGTGGGAAAATTGAATTGGGCAAGTCAGATTTATGCAGGGAT

3320 3330 3340 3350 3360 3370

3230 3240 3250 3260 3270 3280

BH 5 TAAAGTAAGGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACC

:::::::: ::: :::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAAAGTAAAGCAGTTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACC

3380 3390 3400 3410 3420 3430

3290 3300 3310 3320 3330 3340

BH 5 ACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGT

::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::

Licuw, ACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCAGT

3440 3450 3460 3470 3480 3490

3350 3360 3370 3380 3390 3400

BH 5 ACATGGAGTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCA

::::: ::: :::::::::::::::::::::::: :::::::::::::::::::::::::

Licuw, ACATGAAGTATATTATGACCCATCAAAAGACTTAGTAGCAGAAATACAGAAGCAGGGGCA

3500 3510 3520 3530 3540 3550

3410 3420 3430 3440 3450 3460

BH 5 AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAGTA

3560 3570 3580 3590 3600 3610

3470 3480 3490 3500 3510 3520

BH 5 TGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGAGGCAGTGCAAAA

:::::: :::::::::::::::::::::::::::::::: ::::::::::::::::::::

Licuw, TGCAAGGATGAGGGGTGCCCACACTAATGATGTAAAACAGTTAACAGAGGCAGTGCAAAA

3620 3630 3640 3650 3660 3670

3530 3540 3550 3560 3570 3580

BH 5 AATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTACCCATACA

: :: :::::::::::::::::::::::::::::: ::::::::::::::::::::::::

Licuw, AGTATCCACAGAAAGCATAGTAATATGGGGAAAGATTCCTAAATTTAAACTACCCATACA

3680 3690 3700 3710 3720 3730

3590 3600 3610 3620 3630 3640

BH 5 AAAAGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTG

::: :::::::::::: ::::::::: :::::::::::::: :::::::::::::::::

Licuw, AAAGGAAACATGGGAAGCATGGTGGATGGAGTATTGGCAAGCTACCTGGATTCCTGAGTG

3740 3750 3760 3770 3780 3790

3650 3660 3670 3680 3690 3700

BH 5 GGAGTTTGTTAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCAT

::::::::: ::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, GGAGTTTGTCAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCAT

3800 3810 3820 3830 3840 3850

3710 3720 3730 3740 3750 3760

BH 5 AGTAGGAGCAGAAACCTTCTATGTAGATGGGGCAGCTAGCAGGGAGACTAAATTAGGAAA

::::::::::::::: :::::::::::::::::::::: ::::::::::::::::::::

Licuw, AGTAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCTAATAGGGAGACTAAATTAGGAAA

3860 3870 3880 3890 3900 3910

3770 3780 3790 3800 3810 3820

BH 5 AGCAGGATATGTTACTAATAGAGGAAGACAAAAAGTTGTCACCCTAACTGACACAACAAA

:::::::::::::::: : ::::::::::::::::::::: :: :: :::::::::::::

Licuw, AGCAGGATATGTTACTGACAGAGGAAGACAAAAAGTTGTCTCCATAGCTGACACAACAAA

3920 3930 3940 3950 3960 3970

3830 3840 3850 3860 3870 3880

BH 5 TCAGAAGACTGAATTACAAGCAATTCATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TCAGAAGACTGAATTACAAGCAATTCATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAA

3980 3990 4000 4010 4020 4030

3890 3900 3910 3920 3930 3940

BH 5 TATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATAAAAGTGA

::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::

Licuw, CATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATAAGAGTGA

4040 4050 4060 4070 4080 4090

3950 3960 3970 3980 3990 4000

BH 5 ATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGC

:::::::::::::: ::::::::::::::::::::::::::::::::::::::: :::::

Licuw, ATCAGAGTTAGTCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTACCTGGC

4100 4110 4120 4130 4140 4150

4010 4020 4030 4040 4050 4060

BH 5 ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGC

4160 4170 4180 4190 4200 4210

4070 4080 4090 4100 4110 4120

BH 5 TGGAATCAGGAAAATACTATTTTTAGATGGAATAGATAAGGCCCAAGAAGAACATGAGAA

::::::::::::: :::::::::: ::::::::::::::::::::::::::::::::::

Licuw, TGGAATCAGGAAAGTACTATTTTTGAATGGAATAGATAAGGCCCAAGAAGAACATGAGAA

4220 4230 4240 4250 4260 4270

4130 4140 4150 4160 4170 4180

BH 5 ATATCACAATAATTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAA

:::::::: :::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, ATATCACAGTAATTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAA

4280 4290 4300 4310 4320 4330

4190 4200 4210 4220 4230 4240

BH 5 AGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGT

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGT

4340 4350 4360 4370 4380 4390

4250 4260 4270 4280 4290 4300

BH 5/8 AGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACATTTAGAAGGAAAAGTTATCCT

:::::::::::::::::::::::::::::::::::::::: ::::::::::: :::::::

Licuw, AGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACATCTAGAAGGAAAAATTATCCT

4400 4410 4420 4430 4440 4450

4310 4320 4330 4340 4350 4360

BH 5 GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAAACAGG

:::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::

Licuw, GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAGACAGG

4460 4470 4480 4490 4500 4510

4370 4380 4390 4400 4410 4420

BH 5 GCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACA

::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, GCAGGAAACAGCATATTTTCTCTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACA

4520 4530 4540 4550 4560 4570

4430 4440 4450 4460 4470 4480

BH 5 TACAGACAATGGCAGCAATTTCACCAGTGCTACGGTTAAGGCCGCCTGTTGGTGGGCGGG

:::::::::::::::::::::::::::: :::::::::::::::::::::::::::: ::

Licuw, TACAGACAATGGCAGCAATTTCACCAGTACTACGGTTAAGGCCGCCTGTTGGTGGGCAGG

4580 4590 4600 4610 4620 4630

4490 4500 4510 4520 4530 4540

BH 5 AATCAAGCAGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTAT

::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::

Licuw, GATCAAGCAGGAATTTGGCATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTAT

4640 4650 4660 4670 4680 4690

4550 4560 4570 4580 4590 4600

BH 5 GAATAAAGAATTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGAC

:::::: :::::::::::::::::::::::::::::::::::::::::::: ::::::::

Licuw, GAATAATGAATTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACACCTTAAGAC

4700 4710 4720 4730 4740 4750

4610 4620 4630 4640 4650 4660

BH 5 AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGATA

4760 4770 4780 4790 4800 4810

4670 4680 4690 4700 4710 4720

BH 5 CAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACA

::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::

Licuw, CAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAACTACA

4820 4830 4840 4850 4860 4870

4730 4740 4750 4760 4770 4780

BH 5 AAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAAATCCACT

::: ::::::::::::::::::::::::::::::::::::::::::: :: : :::: ::

Licuw, AAAGCAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAACAAAGATCCCCT

4880 4890 4900 4910 4920 4930

4790 4800 4810 4820 4830 4840

BH 5 TTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAA

::::::::::::::::::::: ::::: ::::::::::::::::::::::::::::::::

Licuw, TTGGAAAGGACCAGCAAAGCTTCTCTGCAAAGGTGAAGGGGCAGTAGTAATACAAGATAA

4940 4950 4960 4970 4980 4990

4850 4860 4870 4880 4890 4900

BH 5 TAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACA

:::::::::::::::::::::::::::::::::::: :::::::::::::::::::::::

Licuw, TAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAAATCATTAGGGATTATGGAAAACA

5000 5010 5020 5030 5040 5050

4910 4920 4930 4940 4950 4960

BH 5 GATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACATGGAAAAGTT

::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::

Licuw, GATGGCAGGTGATGATTGTGT---AAGTAGACAGGATGAGGATTAGAACATGGAAAAGTT

5060 5070 5080 5090 5100 5110

4970 4980 4990 5000 5010 5020

BH 5 TAGTAAAACACCATATGTATGTTTCAGGGAAAGCTAGGGGATGGTTTTATAGACATCACT

:::::::::::::::::::: ::::: :::::::: :::::::::: ::: :::::::

Licuw, TAGTAAAACACCATATGTATATTTCAAAGAAAGCTAAAGGATGGTTTT-TAG-CATCACT

5120 5130 5140 5150 5160 5170

5030 5040 5050 5060 5070 5080

BH 5 ATGAAAGCCCTCATCCAAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTAGAT

:::::: ::::::::::: :::::::::::::::::::::: ::::::::::::: ::

Licuw, -TGAAAGTACTCATCCAAGAGTAAGTTCAGAAGTACACATCCCCCTAGGGGATGCTAAAT

5180 5190 5200 5210 5220 5230

5090 5100 5110 5120 5130 5140

BH 5 TGGTAATAACAACATATTGGGGTCTGCATACA-GGAGAAAGAGACTGGCATTTGGGTCAG

:::::::::::::::::::::::::::::::: ::::::::::: ::::::::::: :::

Licuw, TGGTAATAACAACATATTGGGGTCTGCATACAAGGAGAAAGAGAATGGCATTTGGG-CAG

5240 5250 5260 5270 5280

5150 5160 5170 5180 5190 5200

BH 5 GGAGTCTCCATAGAATGGAGGAAAAGGAGATATAGCACACAAGTAGACCCTGAACTAGCA

:: ::: ::::::::::::: ::: :: :::::::::::::::::::: ::::::

Licuw, GG-GTCGCCATAGAATGGAGAAAA----GAATTAGCACACAAGTAGACCCTGGCCTAGCA

5290 5300 5310 5320 5330 5340

5210 5220 5230 5240 5250 5260

BH 5 GACCAACTAATTCATCTGTATTACTTTGATTGTTTTTCAGACTCTGCTATAAGAAAGGCC

:::::::::::::::::: :::: ::::::::::::::::: :::::::::: ::: :::

Licuw, GACCAACTAATTCATCTGCATTATTTTGATTGTTTTTCAGAATCTGCTATAAAAAATGCC

5350 5360 5370 5380 5390 5400

5270 5280 5290 5300 5310 5320

BH 5 TTATTAGGACACATAGTTAGCCCTAGGTGTGAATATCAAGCAGGACATAACAAGGTAGGA

:::::::: : : :::::: ::::: :::::::::::::::::::::::::::::::::

Licuw, ATATTAGGATATAGAGTTAGTCCTAGCTGTGAATATCAAGCAGGACATAACAAGGTAGGA

5410 5420 5430 5440 5450 5460

5330 5340 5350 5360 5370 5380

BH 5 TCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGGGAAAGCCACCTTTG

::::::::::::::::::::::::::::::::::::::::::::: :::::::::::::

Licuw, TCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGACAAAGCCACCTTTG

5470 5480 5490 5500 5510 5520

5390 5400 5410 5420 5430 5440

BH 5 CCTAGTGTTACGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCAC

:::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CCTAGTGTTAAGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCAC

5530 5540 5550 5560 5570 5580

5450 5460 5470 5480 5490 5500

BH 5 AGAGGGAGCCACACAATGAATGGACACTAGAGCTTTTAGAGGAGCTTAAGAATGAAGCTG

::::::::::: ::::::::::::::::::::::::::::::::::::::: :::::::

Licuw, AGAGGGAGCCATACAATGAATGGACACTAGAGCTTTTAGAGGAGCTTAAGAGAGAAGCTG

5590 5600 5610 5620 5630 5640

5510 5520 5530 5540 5550 5560

BH 5 TTAGACATTTTCCTAGGATTTGGCTCCATGGCTTAGGGCAACATATCTATGAAACTTATG

::::::::::::::::: ::::::::: ::::::: ::: ::::::::::::::::::

Licuw, TTAGACATTTTCCTAGGCCATGGCTCCATAGCTTAGGACAATATATCTATGAAACTTATG

5650 5660 5670 5680 5690 5700

5570 5580 5590 5600 5610 5620

BH 5 GGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATCC

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :

Licuw, GGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATTC

5710 5720 5730 5740 5750 5760

5630 5640 5650 5660 5670 5680

BH 5 ATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCAACAGAGGAGAGCAAGA

:::: :::::::::::::: :::::::::::::::: ::: :::::::::::::::::::

Licuw, ATTT-CAGAATTGGGTGTCAACATAGCAGAATAGGCATTATTCAACAGAGGAGAGCAAGA

5770 5780 5790 5800 5810 5820

5690 5700 5710 5720 5730

BH 5 A---ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAA

: ::::::::::::::::::: ::::::::::::::::::::::::::::::::::

Licuw, AGAAATGGAGCCAGTAGATCCTAATCTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAG

5830 5840 5850 5860 5870 5880

5740 5750 5760 5770 5780 5790

BH 5 AACTGCTTGTACCACTTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCAT

:::::::::: :: ::::::::::::::::::::::::::::::: : : :::::::

Licuw, GACTGCTTGTAACAATTGCTATTGTAAAAAGTGTTGCTTTCATTGCTACGCGTGTTTCAC

5890 5900 5910 5920 5930 5940

5800 5810 5820 5830 5840 5850

BH 5 AACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTC

:: ::::: ::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AAGAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTC

5950 5960 5970 5980 5990 6000

5860 5870 5880 5890 5900 5910

BH 8 GAGCTCATCGAAGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAGTAAGTAGTACATGT

:::: :: ::::::::::::::::: ::::::::::::::::::::::::: ::::

Licuw,---CTCAG-GA--CAGTCAGACTCATCAAGCTTCTCTATCAAAGCAGTAAGTAGTAAATGT

6010 6020 6030 6040 6050

5920 5930 5940 5950 5960 5970

BH 8 AATGCAACCTATACAAATA---GCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAAT

::::::: :: :::::::: ::::::::: :::::::::::: : ::::::::::::

Licuw, AATGCAATCTTTACAAATATTAGCAATAGTATCATTAGTAGTAGTAGCAATAATAGCAAT

6060 6070 6080 6090 6100 6110

5980 5990 6000 6010 6020 6030

BH 8 AGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGA

:::::::::: :::::::: ::::::::::::::::::::::::::::::::::: ::::

Licuw, AGTTGTGTGGACCATAGTACTCATAGAATATAGGAAAATATTAAGACAAAGAAAA-TAGA

6120 6130 6140 6150 6160 6170

6040 6050 6060 6070 6080 6090

BH 8 CAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGA

::: :::::::::::: ::: ::::: ::::::::::::::::::::: :::::::: ::

Licuw, CAGATTAATTGATAGAATAAGAGAAAAAGCAGAAGACAGTGGCAATGAAAGTGAAGGGGA

6180 6190 6200 6210 6220 6230

6100 6110 6120 6130 6140

BH 8 ---------AATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTG

: :::::::::::::::::::::: ::::: :::::::::

Licuw, CCAGGAGGAATTATCAGCACTTGTGGAGATGGG------------GCACCTTGCTCCTTG

6240 6250 6260 6270 6280

6150 6160 6170 6180 6190 6200

BH 8 GGATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTTAGGGGTAC

:::::::::::::::::::::::::::::::::::::::::::::: :::: :: ::::

Licuw, GGATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTTTATTATGGAGTAC

6290 6300 6310 6320 6330 6340

6210 6220 6230 6240 6250 6260

BH 8 CTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATA

:::::::::: :::::::: :::::::::::::::::::::::::::: :::::::::::

Licuw, CTGTGTGGAAAGAAGCAACTACCACTCTATTTTGTGCATCAGATGCTAGAGCATATGATA

6350 6360 6370 6380 6390 6400

6270 6280 6290 6300 6310 6320

BH 8 CAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAG

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAG

6410 6420 6430 6440 6450 6460

6330 6340 6350 6360 6370 6380

BH 8 AAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGAAC

:::::::::::: :::::::::::::::::::::::::::::::::: ::::::::::::

Licuw, AAGTAGTATTGGGAAATGTGACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAAC

6470 6480 6490 6500 6510 6520

6390 6400 6410 6420 6430 6440

BH 8 AGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAA

::::::: ::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGATGCAGGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAA

6530 6540 6550 6560 6570 6580

6450 6460 6470 6480 6490 6500

BH 8 CCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTA

::::::::::::::: :::::: :::::::::::: ::: : :::::::::::::::::

Licuw, CCCCACTCTGTGTTACTTTAAATTGCACTGATTTGGGGAAGGCTACTAATACCAATAGTA

6590 6600 6610 6620 6630 6640

6510 6520 6530 6540 6550 6560

BH 8 GTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCA

::: ::: : ::: :::::::: ::::::::::::::::::::::::: ::

Licuw, GTAATTGGAAAGAAGAAATA---AAAGGAGAAATAAAAAACTGCTCTTTCAATATCACCA

6650 6660 6670 6680 6690 6700

6570 6580 6590 6600 6610 6620

BH 8 CAAGCAAAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATAC

:::::: ::::: :::: : ::::::::: ::::: ::::: ::: :::::: :: :::

Licuw, CAAGCATAAGAGATAAGATTCAGAAAGAAAATGCACTTTTTCGTAACCTTGATGTAGTAC

6710 6720 6730 6740 6750 6760

6630 6640 6650 6660 6670

BH 8 CAATAGATAATGATA------CTACCAGCTATAC---------GTTGACAAGTTGTAACA

:::::::::::: :: :::::: :::::: ::::: : ::::::::

Licuw, CAATAGATAATGCTAGTACTACTACCAACTATACCAACTATAGGTTGATACATTGTAACA

6770 6780 6790 6800 6810 6820

6680 6690 6700 6710 6720 6730

BH 8 CCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATT

:::::::::::::::::::::::::::::::: :::::::::::::::::::::::::

Licuw, GATCAGTCATTACACAGGCCTGTCCAAAGGTATCATTTGAGCCAATTCCCATACATTATT

6830 6840 6850 6860 6870 6880

6740 6750 6760 6770 6780 6790

BH 8 GTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGAC

:: ::::::::::::::::::::::::: ::::::::::: ::::::::::::: :::::

Licuw, GTACCCCGGCTGGTTTTGCGATTCTAAAGTGTAATAATAAAACGTTCAATGGAAAAGGAC

6890 6900 6910 6920 6930 6940

6800 6810 6820 6830 6840 6850

BH 8 CATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTC

::::::::::::::::::::::::::::::::::::::::::::::: :::: :::::::

Licuw, CATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAATAGTGTCAACTC

6950 6960 6970 6980 6990 7000

6860 6870 6880 6890 6900

BH 8 AACTG-CTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTC

::::: :::::::::::::::::::::::::::::::::::::::::::::: :::::::

Licuw, AACTGTCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGACAATTTC

7010 7020 7030 7040 7050 7060

6910 6920 6930 6940 6950 6960

BH 8 ACGGACAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACA

::: ::::::::::::::::::::::::::::::: :::::::: :::::: ::::::

Licuw, ACGAACAATGCTAAAACCATAATAGTACAGCTGAATGAATCTGTAGCAATTAACTGTACA

7070 7080 7090 7100 7110 7120

6970 6980 6990 7000 7010 7020

BH 8 AGACCCAACAACAATACAAGAAAAAGTATCCAAATCCAGAGGGGACCAGGGAGAGCATTT

:::::::::::::::::::::::::::::: : :: ::::::::::::::::::

Licuw, AGACCCAACAACAATACAAGAAAAAGTATCTATATA------GGACCAGGGAGAGCATTT

7130 7140 7150 7160 7170

7030 7040 7050 7060 7070 7080

BH 8 GTTACAATAGGAAAAATA---GGAAATATGAGACAAGCACATTGTAACATTAGTAGAGCA

::::: ::::: :::: ::: :::: ::: ::::::::::::::::::::::::::

Licuw, CATACAACAGGAAGAATAATAGGAGATATAAGAAAAGCACATTGTAACATTAGTAGAGCA

7180 7190 7200 7210 7220 7230

7090 7100 7110 7120 7130 7140

BH 8 AAATGGAATGCCACTTTAAAACAGATAGATAGCAAATTAAGAGAACAATTTGGAAATAAT

:::::::: ::::::: ::::::::: :: :::::::::::::: ::::: ::::::

Licuw, CAATGGAATAACACTTTAGAACAGATAGTTAAAAAATTAAGAGAACAGTTTGGGAATAAT

7240 7250 7260 7270 7280 7290

7150 7160 7170 7180 7190 7200

BH 8 AAAACAATAATCTTTAAGCAGTCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTT

::::::::: ::::::: :: :::::::::::::::::::::::::::: ::::::::::

Licuw, AAAACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTT

7300 7310 7320 7330 7340 7350

7210 7220 7230 7240 7250 7260

BH 8 AATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGAGT

:::::: ::::::::::::::::::::::: :::::::::::::::::: ::: :::::

Licuw, AATTGTAGAGGGGAATTTTTCTACTGTAATACAACACAACTGTTTAATAATACATGGAG-

7360 7370 7380 7390 7400 7410

7270 7280 7290 7300 7310

BH 8 ACTAAAGGGTCAAATAACACTGAAGGAAGT---------GACACAATCACCCTCCCATGC

:: :::: :::::::::::: : :::::::::: ::::::::

Licuw, --------GTTAAATCACACTGAAGGAACTAAAGGAAATGACACAATCATACTCCCATGT

7420 7430 7440 7450 7460

7320 7330 7340 7350 7360 7370

BH 8 AGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCC

7470 7480 7490 7500 7510 7520

7380 7390 7400 7410 7420 7430

BH 8 ATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGT

:: : ::::::::::: ::::::::::::::::::::::::::::::::::::::::::

Licuw, ATTGGAGGACAAATTAGTTGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGT

7530 7540 7550 7560 7570 7580

7440 7450 7460 7470 7480 7490

BH 8 GGTAATA--GCAAC-AATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGAC

:::: : : ::: ::::: ::::: ::::::::::::::::::::::::::::::::

Licuw, GGTACAAATGTAACTAATGACACCGAGGTCTTCAGACCTGGAGGAGGAGATATGAGGGAC

7590 7600 7610 7620 7630 7640

7500 7510 7520 7530 7540 7550

BH 8 AATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCA

::::::::::::::::::::::::::::::::: :::::::::::::::::::: :::::

Licuw, AATTGGAGAAGTGAATTATATAAATATAAAGTAATAAAAATTGAACCATTAGGAATAGCA

7650 7660 7670 7680 7690 7700

7560 7570 7580 7590 7600 7610

BH 8 CCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAG---GA

::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, CCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGTAGGA

7710 7720 7730 7740 7750 7760

7620 7630 7640 7650 7660 7670

BH 8 GCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACG

::: :::::::::::::::::::::::::::::::::::::::: :::: :::: :::::

Licuw, GCTATGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGGGCAGTGTCATTGACG

7770 7780 7790 7800 7810 7820

7680 7690 7700 7710 7720 7730

BH 8 CTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTG

::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::

Licuw, CTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAACAGCAGAACAATTTGCTG

7830 7840 7850 7860 7870 7880

7740 7750 7760 7770 7780 7790

BH 8 AGGGCTATTGAGGGCCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCA-GCAGCTC

::::::::::::: ::::: ::::::::::::::::::::::::::::::: :::::::

Licuw, AGGGCTATTGAGGCGCAACAACATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTC

7890 7900 7910 7920 7930 7940

7800 7810 7820 7830 7840 7850

BH 8 CAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGG

::::::::: :::::::::::::::::::::::: ::::::::::::::: :::::::

Licuw, CAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAGGGATCAACAGCTCCTA--GATTTGG

7950 7960 7970 7980 7990 8000

7860 7870 7880 7890 7900 7910

BH 8 GGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAAT

::: :::::::::: :::::::::::::::::::::::::::::::::::::::::::::

Licuw, GGT-GCTCTGGAAA-CTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAAT

8010 8020 8030 8040 8050 8060

7920 7930 7940 7950 7960 7970

BH 8 AAATCTCTGGAACAGATTTGGAATAACATGACCTGGATGGAGTGGGACAGAGAAATTAAC

:::::::::::: : :::::: ::::::::::::: ::: ::::::: ::::::::: ::

Licuw, AAATCTCTGGAAGACATTTGGGATAACATGACCTG-ATGCAGTGGGAAAGAGAAATTGAC

8070 8080 8090 8100 8110 8120

7980 7990 8000 8010 8020 8030

BH 8 AATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAAT

:::::::::: : :::: :: ::::: ::::::::::::: ::::: ::::::::::::

Licuw, AATTACACAAACACAATATACACCTTACTTGAAGAATCGCAGAACCAACAAGAAAAGAAT

8130 8140 8150 8160 8170 8180

8040 8050 8060 8070 8080 8090

BH 8 GAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACA

:::::::::::::: ::::: ::::: ::::::::::::::::::::::::: :::::::

Licuw, GAACAAGAATTATTAGAATTGGATAAGTGGGCAAGTTTGTGGAATTGGTTTAGCATAACA

8190 8200 8210 8220 8230 8240

8100 8110 8120 8130 8140 8150

BH 8 AATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGA

:: ::::::::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, AACTGGCTGTGGTATATAAAGATATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGA

8250 8260 8270 8280 8290 8300

8160 8170 8180 8190 8200 8210

BH 8 ATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCG

:::::::::::::: :::::::::::::::::::::::::::::::: :::::::: ::

Licuw, ATAGTTTTTGCTGTGCTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCA

8310 8320 8330 8340 8350 8360

8220 8230 8240 8250 8260 8270

BH 8 TTTCAGACCCACCTCCCAAACCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAA

:::::::::: :::::: ::::: ::::::::: ::::: ::::: :::::::::

Licuw, TTTCAGACCCGGCTCCCAGTGCCGAG---ACCCGACAG-CCCGACGGAATCGAAGAAGAA

8370 8380 8390 8400 8410

8280 8290 8300 8310 8320 8330

BH 8 GGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTAGCACTTATC

:: :::::::::::::::::::::::: ::::::::::: : :::: :::::::::::::

Licuw, GG-GGAGAGAGAGACAGAGACAGATCCGTTCGATTAGTGGATGGATTCTTAGCACTTATC

8420 8430 8440 8450 8460 8470

8340 8350 8360 8370 8380 8390

BH 8 TGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTG

::::: ::::::::::::::::::::::::::::::: :: ::::::::::::::::::

Licuw, TGGGAAGATCTGCGGAGCCTGTGCCTCTTCAGCTACCGGCGGTTGAGAGACTTACTCTTG

8480 8490 8500 8510 8520 8530

8400 8410 8420 8430 8440 8450

BH 8 ATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGG

:::: : :::::: ::::::: ::::::: : ::::::::::::: ::::::::::::

Licuw, ATTGCAGCGAGGACTGTGGAAATTCTGGGGCACAGGGGGTGGGAA---CTCAAATATTGG

8540 8550 8560 8570 8580 8590

8460 8470 8480 8490 8500 8510

BH 8 TGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAACTTGCTCAAT

:::: :::::: :::::::::: :::::::::::::::::::::::::: :: ::::::

Licuw, TGGAGTCTCCTGCAGTATTGGATTCAGGAACTAAAGAATAGTGCTGTTAGCTGGCTCAAC

8600 8610 8620 8630 8640 8650

8520 8530 8540 8550 8560 8570

BH 8 GCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTATTACAAGCAGCT

:::::::: ::::::::: ::::::::::::::::::::::::::::: :::: ::::

Licuw, GCCACAGCTATAGCAGTAACTGAGGGGACAGATAGGGTTATAGAAGTAGCACAAAGAGCT

8660 8670 8680 8690 8700 8710

8580 8590 8600 8610 8620 8630

BH 8 TATAGAGCCATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTA

:::::::: :::: :::::::: ::::::::: ::::: :::::::::: ::::::::

Licuw, TATAGAGCTATTCTCCACATACATAGAAGAATTAGACA---CTTGGAAAGGCTTTTGCTA

8720 8730 8740 8750 8760 8770

8640 8650 8660 8670 8680 8690

BH 8 TAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTGCTGTAAGGGAAAG

::::::::: : ::::::::::: : ::: ::: :::::: ::::: ::::::::::

Licuw, TAAGATGGGGG---AGTGGTCAAAACG-AGTATGGG-GGATGGTCTGCTATAAGGGAAAG

8780 8790 8800 8810 8820

8700 8710 8720 8730

BH 8 AATGAGACGAGCTGAGCCA------------GCAGCAGATGGGGTGGGAGCAGTATCTCG

::::::::::::::::::: :::::::::::::::::: ::::::::::

Licuw, AATGAGACGAGCTGAGCCACGAGCTGAGCCAGCAGCAGATGGG-TGGGA-CAGTATCTCG

8830 8840 8850 8860 8870 8880

8740 8750 8760 8770 8780 8790

BH 8 AGACCTAGAAAAACATGGAGCAATCACAAGTAGCAATACAGCAGCTACCAATGCTGATTG

:::::: :::::::::::: ::::::::::::::::::::::::::: :::::::::::

Licuw, AGACCTGGAAAAACATGGA--AATCACAAGTAGCAATACAGCAGCTACTAATGCTGATTG

8890 8900 8910 8920 8930 8940

8800 8810 8820 8830 8840 8850

BH 8 TGCTTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGTCACACCTCAGGTACC

::: ::::::::::::::::::::::: ::::::::::::::::::: ::::::::::::

Licuw, TGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCAGACCTCAGGTACC

8950 8960 8970 8980 8990 9000

8860 8870 8880 8890 8900 8910

BH 8 TTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGG

:::::::::::::::::::::::::::: ::::: :::::::::::::::::::::::::

Licuw, TTTAAGACCAATGACTTACAAGGCAGCTTTAGATATTAGCCACTTTTTAAAAGAAAAGGG

9010 9020 9030 9040 9050 9060

8920 8930 8940 8950 8960 8970

BH 8 GGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATCCA

::::::::::::::::::: :::::: :::::::::: :::::::::::::::::: :

Licuw, GGGACTGGAAGGGCTAATTTGGTCCCAAAGAAGACAAGAGATCCTTGATCTGTGGATCTA

9070 9080 9090 9100 9110 9120

8980 8990 9000 9010 9020 9030

BH 8 CCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGATCAGATA

::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::

Licuw, CCACACACAAGGCTACTTCCCTGATTGGCAGAATTACACACCAGGGCCAGGGATCAGATA

9130 9140 9150 9160 9170 9180

9040 9050 9060 9070 9080 9090

BH 8 TCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGAGAAGATAGAAGA

::::::::::::::::::::::: :::::::::::::::::::::::::::: :::::::

Licuw, TCCACTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTTGAGCCAGAGAAGGTAGAAGA

9190 9200 9210 9220 9230 9240

9100 9110 9120 9130 9140 9150

BH 8 AGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGGATGGATGA

:::::: :::::::::::: ::::::::::::::: ::::::::::::::::::: ::

Licuw, GGCCAATGAAGGAGAGAACAA-AGCTTGTTACACCCTATGAGCCTGCATGGGATGGAGGA

9250 9260 9270 9280 9290 9300

9160 9170 9180 9190 9200 9210

BH 8 CCCTGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACATGGC

: : :::: ::::::::::: :::::::::::::::: ::::::::::::::::::::

Licuw, CGCGGAGAAAGAAGTGTTAGTGTGGAGGTTTGACAGCAAACTAGCATTTCATCACATGGC

9310 9320 9330 9340 9350 9360

9220 9230 9240 9250 9260 9270

BH 8 CCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGACATCGAGCTTGCTACAAGGGACT

::::::::::::::::::::::: ::: :::::::::::::::::: ::::::::::::

Licuw, CCGAGAGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAGGGACT

9370 9380 9390 9400 9410 9420

9280 9290 9300 9310 9320 9330

BH 8 TTCCGCTGGGGACTTT--------GCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCT

:::::::::::::::: :::::::::::::::::::::::::::::: ::::

Licuw, TTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGT-CCCT

9430 9440 9450 9460 9470

9340 9350 9360 9370 9380

BH 8 CAGATCCTGCATATAA--------TTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGA

:::::::::::::::: ::::::::::::::::::::::::::::::::::::

Licuw, CAGATGCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGA

9480 9490 9500 9510 9520 9530

9390

BH 8 TCTGAGCCTGGGAGCTC-------------------------------------------

:::::::::::::::::

Licuw, TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCT

9540 9550 9560 9570 9580 9590

------------------------------------------------------------

Licuw, TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGAT

9600 9610 9620 9630 9640 9650

-----------------------------------------

Licuw, CCCTCAGACCCTTTTAGTCAGTGTGGAAAAATCTCTAGCAG

9660 9670 9680 9690 9700

TABLE III

(BH 10 v. LUCIW)

90.0% identity

10 20 30 40 50

BH 10 -TGGAAGGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATCTACCAC

:::::::::::::: :::::: :::::::::: ::::::::::::::::::::::::

Licuw, CTGGAAGGGCTAATTTGGTCCCAAAGAAGACAAGAGATCCTTGATCTGTGGATCTACCAC

10 20 30 40 50 60

60 70 80 90 100 110

BH 10 ACACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGATCAGATATCCA

:::::::::::::::::::::: :::::: ::::::::::::::::::::::::::::::

Licuw, ACACAAGGCTACTTCCCTGATTGGCAGAATTACACACCAGGGCCAGGGATCAGATATCCA

70 80 90 100 110 120

120 130 140 150 160 170

BH 10 CTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGAGAAGTTAGAAGAAGCC

::::::::::::::::::: :::::::::::::::::::::::::::: ::::::: :::

Licuw, CTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTTGAGCCAGAGAAGGTAGAAGAGGCC

130 140 150 160 170 180

180 190 200 210 220 230

BH 10 AACAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCG

:: :::::::::::: :::::::::::::::: ::::::::::::: ::::: ::: ::

Licuw, AATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCTGCATGGGATGGAGGACGCG

190 200 210 220 230 240

240 250 260 270 280 290

BH 10 GAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACATGGCCCGA

:::: ::::::::::: :::::::::::::::: ::::::::::::::::::::::::

Licuw, GAGAAAGAAGTGTTAGTGTGGAGGTTTGACAGCAAACTAGCATTTCATCACATGGCCCGA

250 260 270 280 290 300

300 310 320 330 340 350

BH 10 GAGCTGCATCCGGAGTACTTCAAGAACTGCTGACATCGAGCTTGCTACAAGGGACTTTCC

::::::::::::::::::: ::: :::::::::::::::::: ::::::::::::::::

Licuw, GAGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAGGGACTTTCC

310 320 330 340 350 360

360 370 380 390 400 410

BH 10 GCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGA

:::::::::::::::::::::::::::::::::::::::::::::::::: ::::::::

Licuw, GCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGT-CCCTCAGA

370 380 390 400 410

420 430 440 450 460 470

BH 10 TCCTGCATATAAGCAG-CTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCT

: :::::::::::::: :::::::::::::::::::::::::::::::::::::::::::

Licuw, TGCTGCATATAAGCAGACTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCT

420 430 440 450 460 470

480 490

BH 10 GAGCCTGGGAGCTC----------------------------------------------

::::::::::::::

Licuw, GAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGC

480 490 500 510 520 530

------------------------------------------------------------

Licuw, CTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCC

540 550 560 570 580 590

------------------------------------------------------------

Licuw, TCAGACCCTTTTAGTCAGTGTGGAAAAATCTCTAGCAGTGGCGCCCGAACAGGGACGCGA

600 610 620 630 640 650

500 510 520 530

BH 10 --------------------GAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCA

::::::::::::::::::::::::::::::::::::::::

Licuw, AAGCGAAAGTAGAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCA

660 670 680 690 700 710

540 550 560 570 580 590

BH 10 CGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCT

: ::::::::::::::::::::::::::::::::::::: ::::::::::::::::::

Licuw, CAGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAA--TTTTTGACTAGCGGAGGCT

720 730 740 750 760 770

600 610 620 630 640 650

BH 10 AGAAGGAGAGAGA--TGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGAT

::::::::::::: :::::::::::::::: :::::::::::::::::::::::: ::

Licuw, AGAAGGAGAGAGAGATGGGTGCGAGAGCGTCGGTATTAAGCGGGGGAGAATTAGATAAAT

780 790 800 810 820 830

660 670 680 690 700 710

BH 10 GGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTAT

::::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::

Licuw, GGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAGTTAAAACATATAGTAT

840 850 860 870 880 890

720 730 740 750 760 770

BH 10 GGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAG

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, GGGCAAGCAGGGAGCTAGAACGATTCGCAGTCAATCCTGGCCTGTTAGAAACATCAGAAG

900 910 920 930 940 950

780 790 800 810 820 830

BH 10 GCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTA

:::: ::::::::: ::::::::::::: :::::::::::::::::::::::::::::::

Licuw, GCTGCAGACAAATATTGGGACAGCTACAGCCATCCCTTCAGACAGGATCAGAAGAACTTA

960 970 980 990 1000 1010

840 850 860 870 880 890

BH 10 GATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAG

:::::::::::::::::::::::::::::::::::::::::::: :::::::::::::: ::::::

Licuw, GATCATTATATAATACAGTAGCAACCCTCTATTGTGTACATCAAAGGATAGATGTAAAAG

1020 1030 1040 1050 1060 1070

900 910 920 930 940 950

BH 10 ACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCAC

::::::::::::::::::: ::::::::::::::::::::::::::::::::::: ::::

Licuw, ACACCAAGGAAGCTTTAGAGAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAGGCAC

1080 1090 1100 1110 1120 1130

960 970 980 990 1000

BH 10 AGCAAGCAGCAGCTGA------CACAGGACACAGCAGTCAGGTCAGCCAAAATTACCCTA

::::::::::::::: ::::::: ::::::: ::::::::::::::::::::::

Licuw, AGCAAGCAGCAGCTGCAGCTGGCACAGGAAACAGCAGCCAGGTCAGCCAAAATTACCCTA

1140 1150 1160 1170 1180 1190

1010 1020 1030 1040 1050 1060

BH 10 TAGTGCAGAACATCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATG

::::::::::: : ::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAGTGCAGAACCTACAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATG

1200 1210 1220 1230 1240 1250

1070 1080 1090 1100 1110 1120

BH 10 CATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTAATACCCATGTTTTCAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, CATGGGTAAAAGTAGTAGAAGAAAAGGCTTTCAGCCCAGAAGTAATACCCATGTTTTCAG

1260 1270 1280 1290 1300 1310

1130 1140 1150 1160 1170 1180

BH 10 CATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGAC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGAC

1320 1330 1340 1350 1360 1370

1190 1200 1210 1220 1230 1240

BH 10 ATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGAATGGGATA

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, ATCAAGCAGCCATGCAAATGTTAAAAGAGACTATCAATGAGGAAGCTGCAGAATGGGATA

1380 1390 1400 1410 1420 1430

1250 1260 1270 1280 1290 1300

BH 10 GAGTACATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAA

:::: ::::::::::::::::::::::::::::::::::: :::::::::::::::::::

Licuw, GAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAAATGAGAGAACCAAGGGGAA

1440 1450 1460 1470 1480 1490

1310 1320 1330 1340 1350 1360

BH 10 GTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATC

1500 1510 1520 1530 1540 1550

1370 1380 1390 1400 1410 1420

BH 10 CACCTATCCCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, CACCTATCCCAGTAGGAGAAATCTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG

1560 1570 1580 1590 1600 1610

1430 1440 1450 1460 1470 1480

BH 10 TAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAAGAACCTTTTA

::::::::::::::::::::::::::::::::::::::::::::::::: ::::: ::::

Licuw, TAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTA

1620 1630 1640 1650 1660 1670

1490 1500 1510 1520 1530 1540

BH 10 GAGACTATGTAGACCGGTTCTATAAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTAA

:::: ::::::::::::::::::::::::::::::::::: :::::::::::::: ::::

Licuw, GAGATTATGTAGACCGGTTCTATAAAACTCTAAGAGCCGAACAAGCTTCACAGGATGTAA

1680 1690 1700 1710 1720 1730

1550 1560 1570 1580 1590 1600

BH 10 AAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTT

::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::

Licuw, AAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCAAACCCAGATTGTAAGACTATTT

1740 1750 1760 1770 1780 1790

1610 1620 1630 1640 1650 1660

BH 10 TAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAG

::::::::::::::::::: :::::::::::::::::::::::::::::::::::::: :

Licuw, TAAAAGCATTGGGACCAGCAGCTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTGG

1800 1810 1820 1830 1840 1850

1670 1680 1690 1700 1710 1720

BH 10 GAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATACAG

: :::::::::::::: :::::::::::::::::::: :::::::::::::::::: :::

Licuw, GGGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCCATGAGCCAAGTAACAAATCCAG

1860 1870 1880 1890 1900 1910

1730 1740 1750 1760 1770 1780

BH 10 CTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATGGTTAAGTGTTTCA

::: ::::::::::::::::::::::::::::::::::::::::: :::::::::::::

Licuw, CTAACATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCA

1920 1930 1940 1950 1960 1970

1790 1800 1810 1820 1830 1840

BH 10 ATTGTGGCAAAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTT

:::::::::::::::: :::: ::::: ::::::::::::::::::::::::::: ::

Licuw, ATTGTGGCAAAGAAGG-CACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGG---TT

1980 1990 2000 2010 2020 2030

1850 1860 1870 1880 1890 1900

BH 10 GGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTT

: : ::::::: :::::::::::::::::::::::: ::::::::::::::::::::::

Licuw, TGGAGTGTGGAAGGGAAGGACACCAAATGAAAGATTGCACTGAGAGACAGGCTAATTTTT

2040 2050 2060 2070 2080 2090

1910 1920 1930 1940 1950 1960

BH 10 TAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAG

::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCT--------------

2100 2110 2120 2130

1970 1980 1990 2000 2010 2020

BH 10 AGCCAACAGCCCCACCATTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGA

::::::::::::::::::::::::::::::::::::::

Licuw, ----------------------TCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGA

2140 2150 2160 2170

2030 2040 2050 2060 2070 2080

BH 10 GCTTCAGGTCTGGGGTAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGG

::::::::: ::::: :::: :::::::::: :::::::::::::::::::::::::::

Licuw, GCTTCAGGTTTGGGGAGGAGAAAACAACTCCCTCTCAGAAGCAGGAGCCGATAGACAAGG

2180 2190 2200 2210 2220 2230

2090 2100 2110 2120 2130 2140

BH 10 AACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATAAA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATTAA

2240 2250 2260 2270 2280 2290

2150 2160 2170 2180 2190 2200

BH 10 G-ATAGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAG

: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAG

2300 2310 2320 2330 2340 2350

2210 2220 2230 2240 2250 2260

BH 10 AAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTA

::::::::: ::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, AAGAAATGAATTTGCCAGGAAAATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTA

2360 2370 2380 2390 2400 2410

2270 2280 2290 2300 2310 2320

BH 10 TCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTA

:::::::::::::::: :::::::::: ::::::::::::::::::::::::::::::

Licuw, TCAAAGTAAGACAGTACGATCAGATACCTGTAGAAATCTGTGGACATAAAGCTATAGGTA

2420 2430 2440 2450 2460 2470

2330 2340 2350 2360 2370 2380

BH 10 CAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTG

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTG

2480 2490 2500 2510 2520 2530

2390 2400 2410 2420 2430 2440

BH 10 GTTGCACTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAG

:::: ::::::::::: :::::::: :::::::: :::::::::::::::::::::::::

Licuw, GTTGTACTTTAAATTTCCCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAAGCCAG

2540 2550 2560 2570 2580 2590

2450 2460 2470 2480 2490 2500

BH 10 GAATGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAG

:::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::

Licuw, GAATGGATGGCCCAAAAGTTAAGCAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAG

2600 2610 2620 2630 2640 2650

2510 2520 2530 2540 2550 2560

BH 10 TAGAAATTTGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAGAATC

:::: :: ::::::::::::::::::::::::::::::::::::::::::::::: ::::

Licuw, TAGAGATATGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATC

2660 2670 2680 2690 2700 2710

2570 2580 2590 2600 2610 2620

BH 10 CATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAG

:::::::::::::::::::::: ::::::::::::::::::::::::::::::::: :::

Licuw, CATACAATACTCCAGTATTTGCTATAAAGAAAAAAGACAGTACTAAATGGAGAAAACTAG

2720 2730 2740 2750 2760 2770

2630 2640 2650 2660 2670 2680

BH 10 TAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATAC

:::::::::::::::::::::: :::::::::::::::::::::::::: ::::::::::

Licuw, TAGATTTCAGAGAACTTAATAAAAGAACTCAAGACTTCTGGGAAGTTCAGTTAGGAATAC

2780 2790 2800 2810 2820 2830

2690 2700 2710 2720 2730 2740

BH 10 CACATCCCGCAGGGTTAAAAAA-GAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCA

:::: ::::::::::::::::: ::::::::::::::::::: :::::::::::::::::

Licuw, CACA-CCCGCAGGGTTAAAAAAAGAAAAAATCAGTAACAGTATTGGATGTGGGTGATGCA

2840 2850 2860 2870 2880 2890

2750 2760 2770 2780 2790 2800

BH 10 TATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGT

:: :::::::::::::::::: ::::::: :: :::::::::::::::::::::::::::

Licuw, TACTTTTCAGTTCCCTTAGATAAAGACTTTAGAAAGTATACTGCATTTACCATACCTAGT

2900 2910 2920 2930 2940 2950

2810 2820 2830 2840 2850 2860

BH 10 ATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTG-CTTCCACAGGGATGGAA

:::::::::::::::::::::::::::::::::::::::::: :: ::::::::::::::

Licuw, ATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGGCTGCCACAGGGATGGAA

2960 2970 2980 2990 3000 3010

2870 2880 2890 2900 2910 2920

BH 10 AGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAAAAAACA

::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::::

Licuw, AGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACA

3020 3030 3040 3050 3060 3070

2930 2940 2950 2960 2970 2980

BH 10 AAATCCAGACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGA

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GAATCCAGACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGA

3080 3090 3100 3110 3120 3130

2990 3000 3010 3020 3030 3040

BH 10 AATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGACT

:::::::::::::::::::::::::::::: :::::::: :::::::::::::::::: :

Licuw, AATAGGGCAGCATAGAACAAAAATAGAGGAACTGAGACAGCATCTGTTGAGGTGGGGATT

3140 3150 3160 3170 3180 3190

3050 3060 3070 3080 3090 3100

BH 10 TACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT

3200 3210 3220 3230 3240 3250

3110 3120 3130 3140 3150 3160

BH 10 CCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGT

::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::

Licuw, CCATCCTGATAAATGGACAGTACAGCCTATAATGCTGCCAGAAAAAGACAGCTGGACTGT

3260 3270 3280 3290 3300 3310

3170 3180 3190 3200 3210 3220

BH 10 CAATGACATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGAT

:::::::::::::::::::::::: :::::::::::::::::::::::::: :::::::

Licuw, CAATGACATACAGAAGTTAGTGGGAAAATTGAATTGGGCAAGTCAGATTTATGCAGGGAT

3320 3330 3340 3350 3360 3370

3230 3240 3250 3260 3270 3280

BH 10 TAAAGTAAGGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACC

:::::::: ::: :::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TAAAGTAAAGCAGTTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACC

3380 3390 3400 3410 3420 3430

3290 3300 3310 3320 3330 3340

BH 10 ACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGT

::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::

Licuw, ACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCAGT

3440 3450 3460 3470 3480 3490

3350 3360 3370 3380 3390 3400

BH 10 ACATGGAGTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCA

::::: ::: :::::::::::::::::::::::: :::::::::::::::::::::::::

Licuw, ACATGAAGTATATTATGACCCATCAAAAGACTTAGTAGCAGAAATACAGAAGCAGGGGCA

3500 3510 3520 3530 3540 3550

3410 3420 3430 3440 3450 3460

BH 10 AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAGTA

3560 3570 3580 3590 3600 3610

3470 3480 3490 3500 3510 3520

BH 10 TGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGAGGCAGTGCAAAA

:::::: :::::::::::::::::::::::::::::::: ::::::::::::::::::::

Licuw, TGCAAGGATGAGGGGTGCCCACACTAATGATGTAAAACAGTTAACAGAGGCAGTGCAAAA

3620 3630 3640 3650 3660 3670

3530 3540 3550 3560 3570 3580

BH 10 AATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTACCCATACA

: :: :::::::::::::::::::::::::::::: ::::::::::::::::::::::::

Licuw, AGTATCCACAGAAAGCATAGTAATATGGGGAAAGATTCCTAAATTTAAACTACCCATACA

3680 3690 3700 3710 3720 3730

3590 3600 3610 3620 3630 3640

BH 10 AAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTG

:::::::::::::::: ::::::::: :::::::::::::: :::::::::::::::::

Licuw, AAAGGAAACATGGGAAGCATGGTGGATGGAGTATTGGCAAGCTACCTGGATTCCTGAGTG

3740 3750 3760 3770 3780 3790

3650 3660 3670 3680 3690 3700

BH 10 GGAGTTTGTTAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCAT

::::::::: ::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, GGAGTTTGTCAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCAT

3800 3810 3820 3830 3840 3850

3710 3720 3730 3740 3750 3760

BH 10 AGTAGGAGCAGAAACCTTCTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAA

::::::::::::::: ::::::::::::::::::::::: ::::::::::::::::::::

Licuw, AGTAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCTAATAGGGAGACTAAATTAGGAAA

3860 3870 3880 3890 3900 3910

3770 3780 3790 3800 3810 3820

BH 10 AGCAGGATATGTTACTAACAAAGGAAGACAAAAGGTTGTCCCCCTAACTAACACAACAAA

:::::::::::::::: ::: :::::::::::: :::::: :: :: :: ::::::::::

Licuw, AGCAGGATATGTTACTGACAGAGGAAGACAAAAAGTTGTCTCCATAGCTGACACAACAAA

3920 3930 3940 3950 3960 3970

3830 3840 3850 3860 3870 3880

BH 10 TCAGAAAACTGAGTTACAAGCAATTTATCTAGCTTTGCAGGATTCAGGATTAGAAGTAAA

:::::: ::::: :::::::::::: ::::::::::::::::::: ::::::::::::::

Licuw, TCAGAAGACTGAATTACAAGCAATTCATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAA

3980 3990 4000 4010 4020 4030

3890 3900 3910 3920 3930 3940

BH 10 CATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATAAAAGTGA

:::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::

Licuw, CATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATAAGAGTGA

4040 4050 4060 4070 4080 4090

3950 3960 3970 3980 3990 4000

BH 10 ATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGC

:::::::::::::: ::::::::::::::::::::::::::::::::::::::: :::::

Licuw, ATCAGAGTTAGTCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTACCTGGC

4100 4110 4120 4130 4140 4150

4010 4020 4030 4040 4050 4060

BH 10 ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGC

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGC

4160 4170 4180 4190 4200 4210

4070 4080 4090 4100 4110 4120

BH 10 TGGAATCAGGAAAATACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAA

::::::::::::: :::::::::: :::::::::::::::::::::: :::::::::::

Licuw, TGGAATCAGGAAAGTACTATTTTTGAATGGAATAGATAAGGCCCAAGAAGAACATGAGAA

4220 4230 4240 4250 4260 4270

4130 4140 4150 4160 4170 4180

BH 10 ATATCACAGTAATTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, ATATCACAGTAATTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAA

4280 4290 4300 4310 4320 4330

4190 4200 4210 4220 4230 4240

BH 10 AGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGT

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGT

4340 4350 4360 4370 4380 4390

4250 4260 4270 4280 4290 4300

BH 10 AGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACATTTAGAAGGAAAAGTTATCCT

:::::::::::::::::::::::::::::::::::::::: ::::::::::: :::::::

Licuw, AGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACATCTAGAAGGAAAAATTATCCT

4400 4410 4420 4430 4440 4450

4310 4320 4330 4340 4350 4360

BH 10 GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAAACAGG

:::::::::::::::::::::::::::::::::::::::::::::::::::::: :::::

Licuw, GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAGACAGG

4460 4470 4480 4490 4500 4510

4370 4380 4390 4400 4410 4420

BH 10 GCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACA

::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::::

Licuw, GCAGGAAACAGCATATTTTCTCTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACA

4520 4530 4540 4550 4560 4570

4430 4440 4450 4460 4470 4480

BH 10 TACAGACAATGGCAGCAATTTCACCAGTGCTACGGTTAAGGCCGCCTGTTGGTGGGCGGG

:::::::::::::::::::::::::::: :::::::::::::::::::::::::::: ::

Licuw, TACAGACAATGGCAGCAATTTCACCAGTACTACGGTTAAGGCCGCCTGTTGGTGGGCAGG

4580 4590 4600 4610 4620 4630

4490 4500 4510 4520 4530 4540

BH 10 AATCAAGCAGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTAT

::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::

Licuw, GATCAAGCAGGAATTTGGCATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTAT

4640 4650 4660 4670 4680 4690

4550 4560 4570 4580 4590 4600

BH 10 GAATAAAGAATTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGAC

:::::: :::::::::::::::::::::::::::::::::::::::::::: ::::::::

Licuw, GAATAATGAATTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACACCTTAAGAC

4700 4710 4720 4730 4740 4750

4610 4620 4630 4640 4650 4660

BH 10 AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTA

::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::

Licuw, AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGATA

4760 4770 4780 4790 4800 4810

4670 4680 4690 4700 4710 4720

BH 10 CAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACA

::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::

Licuw, CAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAACTACA

4820 4830 4840 4850 4860 4870

4730 4740 4750 4760 4770 4780

BH 10 AAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAAATCCACT

::: ::::::::::::::::::::::::::::::::::::::::::: :: : :::: ::

Licuw, AAAGCAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAACAAAGATCCCCT

4880 4890 4900 4910 4920 4930

4790 4800 4810 4820 4830 4840

BH 10 TTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAA

::::::::::::::::::::: ::::: ::::::::::::::::::::::::::::::::

Licuw, TTGGAAAGGACCAGCAAAGCTTCTCTGCAAAGGTGAAGGGGCAGTAGTAATACAAGATAA

4940 4950 4960 4970 4980 4990

4850 4860 4870 4880 4890 4900

BH 10 TAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACA

:::::::::::::::::::::::::::::::::::: :::::::::::::::::::::::

Licuw, TAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAAATCATTAGGGATTATGGAAAACA

5000 5010 5020 5030 5040 5050

4910 4920 4930 4940 4950 4960

BH 10 GATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACATGGAAAAGTT

::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::

Licuw, GATGGCAGGTGATGATTGTGT---AAGTAGACAGGATGAGGATTAGAACATGGAAAAGTT

5060 5070 5080 5090 5100 5110

4970 4980 4990 5000 5010 5020

BH 10 TAGTAAAACACCATATGTATGTTTCAGGGAAAGCTAGGGGATGGTTTTATAGACATCACT

:::::::::::::::::::: ::::: :::::::: :::::::::: ::: :::::::

Licuw, TAGTAAAACACCATATGTATATTTCAAAGAAAGCTAAAGGATGGTTTT-TAG-CATCACT

5120 5130 5140 5150 5160 5170

5030 5040 5050 5060 5070 5080

BH 10 ATGAAAGCCCTCATCCAAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTAGAT

:::::: ::::::::::: :::::::::::::::::::::: ::::::::::::: ::

Licuw, -TGAAAGTACTCATCCAAGAGTAAGTTCAGAAGTACACATCCCCCTAGGGGATGCTAAAT

5180 5190 5200 5210 5220 5230

5090 5100 5110 5120 5130 5140

BH 10 TGGTAATAACAACATATTGGGGTCTGCATACA-GGAGAAAGAGACTGGCATTTGGGTCAG

:::::::::::::::::::::::::::::::: ::::::::::: ::::::::::: :::

Licuw, TGGTAATAACAACATATTGGGGTCTGCATACAAGGAGAAAGAGAATGGCATTTGGG-CAG

5240 5250 5260 5270 5280

5150 5160 5170 5180 5190 5200

BH 10 GGAGTCTCCATAGAATGGAGGAAAAAGAGATATAGCACACAAGTAGACCCTGAACTAGCA

:: ::: ::::::::::::: :::::: :: :::::::::::::::::::: ::::::

Licuw, GG-GTCGCCATAGAATGGAG--AAAAGA-AT-TAGCACACAAGTAGACCCTGGCCTAGCA

5290 5300 5310 5320 5330 5340

5210 5220 5230 5240 5250 5260

BH 10 GACCAACTAATTCATCTGTATTACTTTGACTGTTTTTCAGACTCTGCTATAAGAAAGGCC

:::::::::::::::::: :::: ::::: ::::::::::: :::::::::: ::: :::

Licuw, GACCAACTAATTCATCTGCATTATTTTGATTGTTTTTCAGAATCTGCTATAAAAAATGCC

5350 5360 5370 5380 5390 5400

5270 5280 5290 5300 5310 5320

BH 10 TTATTAGGACACATAGTTAGCCCTAGGTGTGAATATCAAGCAGGACATAACAAGGTAGGA

:::::::: : :::::: ::::: :::::::::::::::::::::::::::::::::::

Licuw, ATATTAGGATATAGAGTTAGTCCTAGCTGTGAATATCAAGCAGGACATAACAAGGTAGGA

5410 5420 5430 5440 5450 5460

5330 5340 5350 5360 5370 5380

BH 10 TCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGATAAAGCCACCTTTG

:::::::::::::::::::::::::::::::::::::::::::::: :::::::::::::

Licuw, TCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGACAAAGCCACCTTTG

5470 5480 5490 5500 5510 5520

5390 5400 5410 5420 5430 5440

BH 10 CCTAGTGTTACGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCAC

:::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, CCTAGTGTTAAGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCAC

5530 5540 5550 5560 5570 5580

5450 5460 5470 5480 5490 5500

BH 10 AGAGGGAGCCACACAATGAATGGACACTAGAGCTTTTAGAGGAGCTTAAGAATGAAGCTG

::::::::::: ::::::::::::::::::::::::::::::::::::::: :::::::

Licuw, AGAGGGAGCCATACAATGAATGGACACTAGAGCTTTTAGAGGAGCTTAAGAGAGAAGCTG

5590 5600 5610 5620 5630 5640

5510 5520 5530 5540 5550 5560

BH 10 TTAGACATTTTCCTAGGATTTGGCTCCATGGCTTAGGGCAACATATCTATGAAACTTATG

::::::::::::::::: ::::::::: ::::::: ::: ::::::::::::::::::

Licuw, TTAGACATTTTCCTAGGCCATGGCTCCATAGCTTAGGACAATATATCTATGAAACTTATG

5650 5660 5670 5680 5690 5700

5570 5580 5590 5600 5610 5620

BH 10 GGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATCC

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :

Licuw, GGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATTC

5710 5720 5730 5740 5750 5760

5630 5640 5650 5660 5670 5680

BH 10 ATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGA

:::: :::::::::::::: :::::::::::::::: ::: :: ::::::::::::::::

Licuw, ATTT-CAGAATTGGGTGTCAACATAGCAGAATAGGCATTATTCAACAGAGGAGAGCAAGA

5770 5780 5790 5800 5810 5820

5690 5700 5710 5720 5730

BH 10 A---ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAA

: ::::::::::::::::::: ::::::::::::::::::::::::::::::::::

Licuw, AGAAATGGAGCCAGTAGATCCTAATCTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAG

5830 5840 5850 5860 5870 5880

5740 5750 5760 5770 5780 5790

BH 10 AACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCAT

:::::::::: :::::::::::::::::::::::::::::::::: : : :::::::

Licuw, GACTGCTTGTAACAATTGCTATTGTAAAAAGTGTTGCTTTCATTGCTACGCGTGTTTCAC

5890 5900 5910 5920 5930 5940

5800 5810 5820 5830 5840 5850

BH 10 AACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGACCTCC

:: ::::: :::::::::::::::::::::::::::::::::::::::::::::: ::::

Licuw, AAGAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCC

5950 5960 5970 5980 5990 6000

5860 5870 5880 5890 5900 5910

BH 10 TCAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAGTAAGTAGTACATGTAATGCA

::: : ::::::::::::::::: ::::::::::::::::::::::::: ::::::::::

Licuw, TCAGGACAGTCAGACTCATCAAGCTTCTCTATCAAAGCAGTAAGTAGTAAATGTAATGCA

6010 6020 6030 6040 6050 6060

5920 5930 5940 5950 5960 5970

BH 10 ACCTATACAAATA---GCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGT

: :: :::::::: ::::::::: :::::::::::: : ::::::::::::::::::

Licuw, ATCTTTACAAATATTAGCAATAGTATCATTAGTAGTAGTAGCAATAATAGCAATAGTTGT

6070 6080 6090 6100 6110 6120

5980 5990 6000 6010 6020 6030

BH 10 GTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTT

:::: :::::::: ::::::::::::::::::::::::::::::::::: ::::::: ::

Licuw, GTGGACCATAGTACTCATAGAATATAGGAAAATATTAAGACAAAGAAAA-TAGACAGATT

6130 6140 6150 6160 6170 6180

6040 6050 6060 6070 6080

BH 10 AATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGA------

:::::::::: ::: ::::: ::::::::::::::::::::: :::::::: ::

Licuw, AATTGATAGAATAAGAGAAAAAGCAGAAGACAGTGGCAATGAAAGTGAAGGGGACCAGGA

6190 6200 6210 6220 6230 6240

6090 6100 6110 6120 6130 6140

BH 10 ---AATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGT

: ::::::::::::::::::::::: :::: :::::::::::::::

Licuw, GGAATTATCAGCACTTGTGGAGATGGGG------------CACCTTGCTCCTTGGGATGT

6250 6260 6270 6280 6290

6150 6160 6170 6180 6190 6200

BH 10 TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGT

:::::::::::::::::::::::::::::::::::::::: :::::::: ::::::::::

Licuw, TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTTTATTATGGAGTACCTGTGT

6300 6310 6320 6330 6340 6350

6210 6220 6230 6240 6250 6260

BH 10 GGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGG

:::: :::::::: :::::::::::::::::::::::::::: :::::::::::::::::

Licuw, GGAAAGAAGCAACTACCACTCTATTTTGTGCATCAGATGCTAGAGCATATGATACAGAGG

6360 6370 6380 6390 6400 6410

6270 6280 6290 6300 6310 6320

BH 10 TACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAG

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAG

6420 6430 6440 6450 6460 6470

6330 6340 6350 6360 6370 6380

BH 10 TATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGAACAGATGC

:::::: :::::::::::::::::::::::::::::::::: ::::::::::::::::::

Licuw, TATTGGGAAATGTGACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAACAGATGC

6480 6490 6500 6510 6520 6530

6390 6400 6410 6420 6430 6440

BH 10 ATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCAC

: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, AGGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCAC

6540 6550 6560 6570 6580 6590

6450 6460 6470 6480 6490 6500

BH 10 TCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCG

::::::::: :::::: :::::::::::: ::: : ::::::::::::::::::::

Licuw, TCTGTGTTACTTTAAATTGCACTGATTTGGGGAAGGCTACTAATACCAATAGTAGTAATT

6600 6610 6620 6630 6640 6650

6510 6520 6530 6540 6550 6560

BH 10 GGAGA-ATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGC

::: : : :: ::: :::::::: ::::::::::::::::::::::::: :::::::

Licuw, GGAAAGAAGA-AATA---AAAGGAGAAATAAAAAACTGCTCTTTCAATATCACCACAAGC

6660 6670 6680 6690 6700

6570 6580 6590 6600 6610 6620

BH 10 ATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATA

::::::: :::: : ::::::::: ::::: ::::: ::: :::::: :: ::::::::

Licuw, ATAAGAGATAAGATTCAGAAAGAAAATGCACTTTTTCGTAACCTTGATGTAGTACCAATA

6710 6720 6730 6740 6750 6760

6630 6640 6650 6660

BH 10 GATAATGATA------CTACCAGCTATAC---------GTTGACAAGTTGTAACACCTCA

::::::: :: :::::: :::::: ::::: : :::::::: :::

Licuw, GATAATGCTAGTACTACTACCAACTATACCAACTATAGGTTGATACATTGTAACAGATCA

6770 6780 6790 6800 6810 6820

6670 6680 6690 6700 6710 6720

BH 10 GTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTGCC

::::::::::::::::::::::::::::: ::::::::::::::::::::::::::: ::

Licuw, GTCATTACACAGGCCTGTCCAAAGGTATCATTTGAGCCAATTCCCATACATTATTGTACC

6830 6840 6850 6860 6870 6880

6730 6740 6750 6760 6770 6780

BH 10 CCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGT

::::::::::::::::::::::: ::::::::::: ::::::::::::: ::::::::::

Licuw, CCGGCTGGTTTTGCGATTCTAAAGTGTAATAATAAAACGTTCAATGGAAAAGGACCATGT

6890 6900 6910 6920 6930 6940

6790 6800 6810 6820 6830 6840

BH 10 ACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTG

:::::::::::::::::::::::::::::::::::::::::: :::: ::::::::::::

Licuw, ACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAATAGTGTCAACTCAACTG

6950 6960 6970 6980 6990 7000

6850 6860 6870 6880 6890 6900

BH 10 -CTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGCCAATTTCACAGA

:::::::::::::::::::::::::::::::::::::::::::::: ::::::::: :

Licuw, TCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGACAATTTCACGAA

7010 7020 7030 7040 7050 7060

6910 6920 6930 6940 6950 6960

BH 10 CAATGCTAAAACCATAATAGTACAGCTGAACCAATCTGTAGAAATTAATTGTACAAGACC

:::::::::::::::::::::::::::::: ::::::::: :::::: :::::::::::

Licuw, CAATGCTAAAACCATAATAGTACAGCTGAATGAATCTGTAGCAATTAACTGTACAAGACC

7070 7080 7090 7100 7110 7120

6970 6980 6990 7000 7010 7020

BH 10 CAACAACAATACAAGAAAAAGTATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTAC

::::::::::::::::::::::::: ::: ::::::::::::::::::: :::

Licuw, CAACAACAATACAAGAAAAAGTATCTATAT------AGGACCAGGGAGAGCATTTCATAC

7130 7140 7150 7160 7170 7180

7030 7040 7050 7060 7070 7080

BH 10 AATAGGAAAAATA---GGAAATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAATG

:: ::::: :::: ::: :::: ::: :::::::::::::::::::::::::: ::::

Licuw, AACAGGAAGAATAATAGGAGATATAAGAAAAGCACATTGTAACATTAGTAGAGCACAATG

7190 7200 7210 7220 7230 7240

7090 7100 7110 7120 7130 7140

BH 10 GAATAACACTTTAAAACAGATAGATAGCAAATTAAGAGAACAATTTGGAAATAATAAAAC

::::::::::::: ::::::::: :: :::::::::::::: ::::: :::::::::::

Licuw, GAATAACACTTTAGAACAGATAGTTAAAAAATTAAGAGAACAGTTTGGGAATAATAAAAC

7250 7260 7270 7280 7290 7300

7150 7160 7170 7180 7190 7200

BH 10 AATAATCTTTAAGCAGTCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTG

:::: ::::::: :: :::::::::::::::::::::::::::: :::::::::::::::

Licuw, AATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTG

7310 7320 7330 7340 7350 7360

7210 7220 7230 7240 7250 7260

BH 10 TGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGT--TTAAT

: ::::::::::::::::::::::: :::::::::::::::::: ::: ::: ::::

Licuw, TAGAGGGGAATTTTTCTACTGTAATACAACACAACTGTTTAATAATACATGGAGGTTAA-

7370 7380 7390 7400 7410

7270 7280 7290 7300 7310 7320

BH 10 AGTACTTGGAGTACTAAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCA

: :: ::: :::: ::: :::::: ::::::::::: ::::::

Licuw, ATCAC-------ACTGAAGGA---------ACTAAAGGAAATGACACAATCATACTCCCA

7420 7430 7440 7450 7460

7330 7340 7350 7360 7370 7380

BH 10 TGCAGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCT

:: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, TGTAGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCT

7470 7480 7490 7500 7510 7520

7390 7400 7410 7420 7430 7440

BH 10 CCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGAT

::::: : ::::::::::: :::::::::::::::::::::::::::::::::::::::

Licuw, CCCATTGGAGGACAAATTAGTTGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGAT

7530 7540 7550 7560 7570 7580

7450 7460 7470 7480 7490 7500

BH 10 GGTGGTAATA--GCAAC-AATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGG

::::::: : : ::: ::::: ::::: :::::::::::::::::::::::::::::

Licuw, GGTGGTACAAATGTAACTAATGACACCGAGGTCTTCAGACCTGGAGGAGGAGATATGAGG

7590 7600 7610 7620 7630 7640

7510 7520 7530 7540 7550 7560

BH 10 GACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTA

:::::::::::::::::::::::::::::::::::: :::::::::::::::::::: ::

Licuw, GACAATTGGAGAAGTGAATTATATAAATATAAAGTAATAAAAATTGAACCATTAGGAATA

7650 7660 7670 7680 7690 7700

7570 7580 7590 7600 7610

BH 10 GCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAG--

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Licuw, GCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGTA

7710 7720 7730 7740 7750 7760

7620 7630 7640 7650 7660 7670

BH 10 -GAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATG

::::: :::::::::::::::::::::::::::::::::::::::: :::: :::: ::

Licuw, GGAGCTATGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGGGCAGTGTCATTG

7770 7780 7790 7800 7810 7820

7680 7690 7700 7710 7720 7730

BH 10 ACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG

:::::::::::::::::::::::::::::::::::::::::::: :::::::::::::::

Licuw, ACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAACAGCAGAACAATTTG

7830 7840 7850 7860 7870 7880

7740 7750 7760 7770 7780 7790

BH 10 CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAG

::::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::

Licuw, CTGAGGGCTATTGAGGCGCAACAACATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAG

7890 7900 7910 7920 7930 7940

7800 7810 7820 7830 7840 7850

BH 10 CTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATT

:::::::::::: :::::::::::::::::::::::: ::::::::::::::: : :::

Licuw, CTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAGGGATCAACAGCTCCTAG--ATT

7950 7960 7970 7980 7990 8000

7860 7870 7880 7890 7900 7910

BH 10 TGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT

:::::: :::::::::: ::::::::::::::::::::::::::::::::::::::::::

Licuw, TGGGGT-GCTCTGGAAA-CTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT

8010 8020 8030 8040 8050

7920 7930 7940 7950 7960 7970

BH 10 AATAAATCTCTGGAACAGATTTGGAATAACATGACCTGGATGGAGTGGGACAGAGAAATT

::::::::::::::: : :::::: ::::::::::::: ::: ::::::: :::::::::

Licuw, AATAAATCTCTGGAAGACATTTGGGATAACATGACCTG-ATGCAGTGGGAAAGAGAAATT

8060 8070 8080 8090 8100 8110

7980 7990 8000 8010 8020 8030

BH 10 AACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAG

:::::::::::: : :::: :: ::::: ::::::::::::: ::::: :::::::::

Licuw, GACAATTACACAAACACAATATACACCTTACTTGAAGAATCGCAGAACCAACAAGAAAAG

8120 8130 8140 8150 8160 8170

8040 8050 8060 8070 8080 8090

BH 10 AATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATA

::::::::::::::::: ::::: ::::: ::::::::::::::::::::::::: ::::

Licuw, AATGAACAAGAATTATTAGAATTGGATAAGTGGGCAAGTTTGTGGAATTGGTTTAGCATA

8180 8190 8200 8210 8220 8230

8100 8110 8120 8130 8140 8150

BH 10 ACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTA

::::: ::::::::::::::::: :::::::::::::::::::::::::::::::::::

Licuw, ACAAACTGGCTGTGGTATATAAAGATATTCATAATGATAGTAGGAGGCTTGGTAGGTTTA

8240 8250 8260 8270 8280 8290

8160 8170 8180 8190 8200 8210

BH 10 AGAATAGTTTTTGCTGTACTTTCTGTAGTGAATAGAGTTAGGCAGGGATATTCACCATTA

::::::::::::::::: :::::: ::::::::::::::::::::::::: :::::::::

Licuw, AGAATAGTTTTTGCTGTGCTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTG

8300 8310 8320 8330 8340 8350

8220 8230 8240 8250 8260 8270

BH 10 TCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAA

:: :::::::::: :::::: : ::::: ::::::::: ::::: ::::: ::::::

Licuw, TCATTTCAGACCCGGCTCCCAGTGCCGAG---ACCCGACAG-CCCGACGGAATCGAAGAA

8360 8370 8380 8390 8400 8410

8280 8290 8300 8310 8320 8330

BH 10 GAAGGGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTAGCACTTA

::::::::::::::::::::::::::::: ::::::::::: : :::: :::::::::::

Licuw, GAAGGGGAGAGAGAGACAGAGACAGATCCGTTCGATTAGTGGATGGATTCTTAGCACTTA

8420 8430 8440 8450 8460 8470

8340 8350 8360 8370 8380 8390

BH 10 TCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCT

::::::: ::::::::::::::::::::::::::::::: :: ::::::::::::::::

Licuw, TCTGGGAAGATCTGCGGAGCCTGTGCCTCTTCAGCTACCGGCGGTTGAGAGACTTACTCT

8480 8490 8500 8510 8520 8530

8400 8410 8420 8430 8440 8450

BH 10 TGATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATT

:::::: : :::::: ::::::: ::::::: : ::::::::::::: ::::::::::

Licuw, TGATTGCAGCGAGGACTGTGGAAATTCTGGGGCACAGGGGGTGGGAA---CTCAAATATT

8540 8550 8560 8570 8580 8590

8460 8470 8480 8490 8500 8510

BH 10 GGTGGAATCTCCTACAGTATTGGAGTCAGGAGCTAAAGAATAGTGCTGTTAGCTTGCTCA

:::::: :::::: :::::::::: :::::: :::::::::::::::::::::: :::::

Licuw, GGTGGAGTCTCCTGCAGTATTGGATTCAGGAACTAAAGAATAGTGCTGTTAGCTGGCTCA

8600 8610 8620 8630 8640 8650

8520 8530 8540 8550 8560 8570

BH 10 ATGCCACAGCTATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAG

: :::::::::::::::::: :::::::::::::::::::::::::::::: :::: :::

Licuw, ACGCCACAGCTATAGCAGTAACTGAGGGGACAGATAGGGTTATAGAAGTAGCACAAAGAG

8660 8670 8680 8690 8700 8710

8580 8590 8600 8610 8620 8630

BH 10 CTTATAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGC

::::::::::::::: :::::::: ::::::::: ::::: :::::::::: ::::::

Licuw, CTTATAGAGCTATTCTCCACATACATAGAAGAATTAGACA---CTTGGAAAGGCTTTTGC

8720 8730 8740 8750 8760

8640 8650 8660 8670 8680 8690

BH 10 TATAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTGCTGTAAGGGAA

::::::::::: : ::::::::::: : ::: ::: :::::: ::::: ::::::::

Licuw, TATAAGATGGGGG---AGTGGTCAAAACG-AGTATGGG-GGATGGTCTGCTATAAGGGAA

8770 8780 8790 8800 8810 8820

8700 8710 8720 8730 8740

BH 10 AGAATGAGACGAGCTGAGCCA------------GCAGCAGATGGGGTGGGAGCAGCATCT

::::::::::::::::::::: :::::::::::: ::::: ::: ::::

Licuw, AGAATGAGACGAGCTGAGCCACGAGCTGAGCCAGCAGCAGATGGG-TGGGA-CAGTATCT

8830 8840 8850 8860 8870 8880

8750 8760 8770 8780 8790 8800

BH 10 CGAGACCTAGAAAAACATGGAGCAATCACAAGTAGCAACACAGCAGCTAACAATGCTGAT

:::::::: :::::::::::: ::::::::::::::: :::::::::: :::::::::

Licuw, CGAGACCTGGAAAAACATGGA--AATCACAAGTAGCAATACAGCAGCTACTAATGCTGAT

8890 8900 8910 8920 8930

8810 8820 8830 8840 8850 8860

BH 10 TGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGTCACACCTCAGGTA

::::::::::::::::::::::::::::: ::::::::::::::::::: ::::::::::

Licuw, TGTGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCAGACCTCAGGTA

8940 8950 8960 8970 8980 8990

8870 8880 8890 8900 8910 8920

BH 10 CCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAG

:::::::::::::::::::::::::::::: ::::: :::::::::::::::::::::::

Licuw, CCTTTAAGACCAATGACTTACAAGGCAGCTTTAGATATTAGCCACTTTTTAAAAGAAAAG

9000 9010 9020 9030 9040 9050

8930 8940 8950 8960 8970 8980

BH 10 GGGGGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATC

::::::::::::::::::::: :::::: :::::::::: ::::::::::::::::::

Licuw, GGGGGACTGGAAGGGCTAATTTGGTCCCAAAGAAGACAAGAGATCCTTGATCTGTGGATC

9060 9070 9080 9090 9100 9110

8990 9000 9010 9020 9030 9040

BH 10 TACCACACACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGATCAGA

:::::::::::::::::::::::::::: :::::: ::::::::::::::::::::::::

Licuw, TACCACACACAAGGCTACTTCCCTGATTGGCAGAATTACACACCAGGGCCAGGGATCAGA

9120 9130 9140 9150 9160 9170

9050 9060 9070 9080 9090 9100

BH 10 TATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGAGAAGTTAGAA

::::::::::::::::::::::::: :::::::::::::::::::::::::::: :::::

Licuw, TATCCACTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTTGAGCCAGAGAAGGTAGAA

9180 9190 9200 9210 9220 9230

9110 9120 9130 9140 9150 9160

BH 10 GAAGCCAACAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGAT

:: ::::: :::::::::::: ::::::::::::::: ::::::::::::: :::::

Licuw, GAGGCCAATGAAGGAGAGAACAA-AGCTTGTTACACCCTATGAGCCTGCATGGGATGGAG

9240 9250 9260 9270 9280 9290

9170 9180 9190 9200 9210 9220

BH 10 GACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACATG

::: :::::: ::::::::::: :::::::::::::::: ::::::::::::::::::

Licuw, GACGCGGAGAAAGAAGTGTTAGTGTGGAGGTTTGACAGCAAACTAGCATTTCATCACATG

9300 9310 9320 9330 9340 9350

9230 9240 9250 9260 9270 9280

BH 10 GCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGACATCGAGCTTGCTACAAGGGA

::::::::::::::::::::::::: ::: :::::::::::::::::: ::::::::::

Licuw, GCCCGAGAGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAGGGA

9360 9370 9380 9390 9400 9410

9290 9300 9310 9320 9330 9340

BH 10 CTTTCCGCTGGGGACTTTCCAGG-AGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCC

::::::::::::::::::::::: :::::::::::::::::::::::::::::::: ::

Licuw, CTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGT-CC

9420 9430 9440 9450 9460 9470

9350 9360 9370 9380 9390 9400

BH 10 CTCAGATCCTGCATATAAGGAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCA

::::::: ::::::::::: ::::::::::::::::::::::::::::::::::::::::

Licuw, CTCAGATGCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCA

9480 9490 9500 9510 9520 9530

9410 9420

BH 10 GATCTGAGCCTGGGAGCTC-----------------------------------------

:::::::::::::::::::

Licuw, GATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAG

9540 9550 9560 9570 9580 9590

BH 10 ------------------------------------------------------------

Licuw, CTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAG

9600 9610 9620 9630 9640 9650

BH 10 -------------------------------------------

Licuw, ATCCCTCAGACCCTTTTAGTCAGTGTGGAAAAATCTCTAGCAG

9660 9670 9680 9690 9700

Claims

1. A composition comprising a duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the duplex is outside of a mammalian cell and outside of an HIV-1 particle;wherein the duplex comprises a double-stranded region of at least 18 contiguous nucleotides and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein the single-stranded nucleic acid comprises a label.
2. The composition of claim 1, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
3. The composition of claim 1, wherein the single-stranded nucleic acid is selected from the group consisting of: (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a nucleotide sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a nucleotide sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a nucleotide sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a nucleotide sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a nucleotide sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region.
4. The composition of claim 1, wherein the duplex is bound to a solid support.
5. The composition of claim 1, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
6. The composition of claim 1, wherein the single-stranded nucleic acid comprises DNA.
7. The composition of claim 1, wherein the single-stranded nucleic acid comprises RNA.
8. The composition of claim 1, wherein single-stranded nucleic acid is a cDNA.
9. The composition of claim 1, wherein the label is attached to the single-stranded nucleic acid and wherein the label is not an additional nucleic acid.
10. The composition of claim 1, wherein the single-stranded nucleic acid comprises a non-HIV-1 nucleotide sequence.
11. The composition of claim 1, wherein the single-stranded nucleic acid is chemically made at least in part.
12. The composition of claim 1, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
13. The composition of claim 1, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
14. A method for preparing a DNA construct specific for Human Immunodeficiency Virus Type-1 (HIV-1) comprising the step of inserting into a vector a nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;whereby a DNA construct comprising an inserted nucleic acid is obtained.
15. The method according to claim 14, wherein the DNA construct permits making an RNA transcript of the inserted nucleic acid.
16. A method for replicating DNA specific for HIV-1 comprising the step of growing a cell containing the DNA construct of claim 14 under conditions whereby the inserted nucleic acid is replicated.
17. A method for producing a recombinant HIV-1 polypeptide comprising the step of growing a cell containing the DNA construct of claim 14 under conditions whereby the inserted nucleic acid is expressed to allow production of the recombinant HIV-1 polypeptide in the cell.
18. A nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid; and wherein the nucleic acid is covalently attached to a solid support.
19. The nucleic acid of claim 18, wherein the nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
20. The nucleic acid of claim 18, wherein the nucleic acid is selected from the group consisting of (i) a nucleic acid consisting of from 18 to 103 nucleotides comprising a nucleotide sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
21. The nucleic acid of claim 18, wherein the nucleic acid is a restriction fragment from an HIV-1 nucleic acid.
22. The nucleic acid of claim 18, wherein the nucleic acid is randomly generated from an HIV-1 nucleic acid.
23. The nucleic acid of claim 18, wherein the nucleic acid comprises DNA.
24. The nucleic acid of claim 18, wherein the nucleic acid comprises RNA.
25. The nucleic acid of claim 18, wherein the nucleic acid is a cDNA.
26. The nucleic acid of claim 18, wherein the nucleic acid comprises a label.
27. The nucleic acid of claim 18, wherein the nucleic acid comprises a non-HIV-1 nucleotide sequence.
28. The nucleic acid of claim 18, wherein the nucleic acid is chemically made at least in part.
29. The nucleic acid of claim 18, wherein the nucleic acid is a double-stranded nucleic acid.
30. The nucleic acid of claim 18, wherein the nucleic acid is a single-stranded nucleic acid.
31. A single-stranded nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the single-stranded nucleic acid is within a duplex comprising the HIV-1 nucleic acid; andwherein the duplex is covalently attached to a solid support.
32. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid is complementary to a sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
33. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid is selected from the group consisting of (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
34. The single-stranded nucleic acid of claim 31, wherein the HIV-1 nucleic acid is bound to a solid support.
35. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
36. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid comprises DNA.
37. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid comprises RNA.
38. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid is a cDNA.
39. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid comprises a label.
40. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid comprises a non-HIV-1 nucleotide sequence.
41. The single-stranded nucleic acid of claim 31, wherein the single-stranded nucleic acid is chemically made at least in part.
42. The single-stranded nucleic acid of claim 31, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
43. The single-stranded nucleic acid of claim 31, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
44. A nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the nucleic acid comprises a detectable label covalently attached to the nucleic acid; andwherein the detectable label is not an additional nucleic acid.
45. The nucleic acid of claim 44, wherein the nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
46. The nucleic acid of claim 44, wherein the nucleic acid is selected from the group consisting of (i) a nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region n; and(v) a nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
47. The nucleic acid of claim 44, wherein the nucleic acid is a restriction fragment from an HIV-1 nucleic acid.
48. The nucleic acid of claim 44, wherein the nucleic acid is randomly generated from an HIV-1 nucleic acid.
49. The nucleic acid of claim 44, wherein the nucleic acid comprises DNA.
50. The nucleic acid of claim 44, wherein the nucleic acid comprises RNA.
51. The nucleic acid of claim 44, wherein the nucleic acid is a cDNA.
52. The nucleic acid of claim 44, wherein the nucleic acid comprises a non-HIV-1 nucleotide sequence.
53. The nucleic acid of claim 44, wherein the nucleic acid is chemically made at least in part.
54. The nucleic acid of claim 44, wherein the nucleic acid is a double-stranded nucleic acid.
55. The nucleic acid of claim 44, wherein the nucleic acid is a single-stranded nucleic acid.
56. A nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the nucleic acid is outside of a mammalian cell and outside of a viral particle; andwherein the nucleic acid is attached to a non-HIV-1 nucleic acid through a covalent bond.
57. The nucleic acid of claim 56, wherein the nucleic acid is complementary to a sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
58. The nucleic acid of claim 56, wherein the nucleic acid is selected from the group consisting of (i) a nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
59. The nucleic acid of claim 56, wherein the nucleic acid is a restriction fragment from an HIV-1 nucleic acid.
60. The nucleic acid of claim 56, wherein the nucleic acid is randomly generated from an HIV-1 nucleic acid.
61. The nucleic acid of claim 56, wherein the nucleic acid comprises DNA.
62. The nucleic acid of claim 56, wherein the nucleic acid comprises RNA.
63. The nucleic acid of claim 56, wherein the nucleic acid is a cDNA.
64. The nucleic acid of claim 56, wherein the nucleic acid comprises a label.
65. The nucleic acid of claim 56, wherein the nucleic acid is chemically made at least in part.
66. The nucleic acid of claim 56, wherein the nucleic acid is a double-stranded nucleic acid.
67. The nucleic acid of claim 56, wherein the nucleic acid is a single-stranded nucleic acid.
68. A composition comprising a duplex formed between: (A) a single-stranded nucleic acid of between 18 and 103 contiguous nucleotides and comprising a nucleotide sequence selected from the group consisting of:(i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; and(B) an HIV-1 nucleic acid selected from the group consisting of:(a) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length gag polypeptide or its complement;(b) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length pol polypeptide or its complement;(c) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length env polypeptide or its complement; and(d) an HIV-1 nucleic acid comprising a nucleotide sequence for a long terminal repeat region comprising R and U3 regions or their complements;wherein the single-stranded nucleic acid of (A) does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid of (A) forms a duplex with the HIV-1 nucleic acid of (B);wherein the duplex is outside of a mammalian cell and outside of a viral particle;wherein the duplex comprises a double-stranded region of between 18 and 103 contiguous nucleotides and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein the single-stranded nucleic acid comprises a label.
69. The composition of claim 68, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
70. The composition of claim 68, wherein the single-stranded nucleic acid is selected from the group consisting of (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
71. The composition of claim 68, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
72. The composition of claim 68, wherein the single-stranded nucleic acid comprises DNA.
73. The composition of claim 68, wherein the single-stranded nucleic acid comprises RNA.
74. The composition of claim 68, wherein the single-stranded nucleic acid is a cDNA.
75. The composition of claim 68, wherein the label is attached to the single-stranded nucleic acid and wherein the label is not an additional nucleic acid.
76. The composition of claim 68, wherein the single-stranded nucleic acid comprises a non-HIV-1 nucleotide sequence.
77. The composition of claim 68, wherein the single-stranded nucleic acid is chemically made at least in part.
78. The composition of claim 68, wherein the single-stranded nucleic acid is bound to a solid support.
79. The composition of claim 68, wherein the duplex is bound to a solid support.
80. The composition of claim 68, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
81. The composition of claim 68, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
82. A composition comprising: (A) a duplex; and(B) a compound selected from the group consisting of sodium saline citrate, formamide, and dextran sulfate; wherein the duplex comprises a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid having a length of at least 300 nucleotides hybridized to a single-stranded nucleic acid of between 18 and 103 contiguous nucleotides and comprising a nucleotide sequence selected from the group consisting of:(i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid; andwherein the duplex comprises a double-stranded region and a single-stranded region that is longer than the double-stranded region.
83. The composition of claim 82, wherein the single-stranded nucleic acid comprises a sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
84. The composition of claim 82, wherein the single-stranded nucleic acid is selected from the group consisting of (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
85. The composition of claim 82, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
86. The composition of claim 82, wherein the single-stranded nucleic acid comprises DNA.
87. The composition of claim 82, wherein the single-stranded nucleic acid comprises RNA.
88. The composition of claim 82, wherein the single-stranded nucleic acid is a cDNA.
89. The composition of claim 82, wherein the single-stranded nucleic acid comprises a label.
90. The composition of claim 82, wherein the single-stranded nucleic acid comprises a non-HIV-1 nucleotide sequence.
91. The composition of claim 82, wherein the single-stranded nucleic acid is chemically made at least in part.
92. The composition of claim 82, wherein the single-stranded nucleic acid is bound to a solid support.
93. The composition of claim 82, wherein the duplex is bound to a solid support.
94. The composition of claim 82, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
95. The composition of claim 82, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
96. A composition comprising a duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid of at least 18 contiguous nucleotides and comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the single-stranded nucleic acid consists of DNA;wherein the duplex is outside of a mammalian cell;wherein the duplex comprises a double-stranded region of at least 18 contiguous nucleotides and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein the duplex is bound to a solid support.
97. The composition of claim 96, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
98. The composition of claim 96, wherein the single-stranded nucleic acid is selected from the group consisting of: (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a nucleotide sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a nucleotide sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a nucleotide sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a nucleotide sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a nucleotide sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 env open reading frame, an HIV-1 pol open reading frame or from an HIV-1 long terminal repeat region.
99. The composition of claim 96, further comprising a compound selected from the group consisting of sodium saline citrate, formamide, and dextran sulfate.
100. The composition of claim 96, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
101. The composition of claim 96, wherein the single-stranded nucleic acid comprises a label.
102. The composition of claim 96, wherein the single-stranded nucleic acid comprises a non-HIV-1 DNA nucleotide sequence.
103. The composition of claim 96, wherein the single-stranded nucleic acid is chemically made at least in part.
104. The composition of claim 96, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
105. The composition of claim 96, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
106. A single-stranded nucleic acid of at least 18 contiguous nucleotides comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the single-stranded nucleic acid is outside of a mammalian cell and outside of a viral particle;wherein the single-stranded nucleic acid consists of DNA; andwherein the single-stranded nucleic acid is attached to a non-HIV-1 DNA nucleic acid through a covalent bond.
107. The single-stranded nucleic acid of claim 106, wherein the nucleic acid is complementary to a sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
108. The single-stranded nucleic acid of claim 106, wherein the single-stranded nucleic acid is selected from the group consisting of (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
109. The single-stranded nucleic acid of claim 106, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
110. The single-stranded nucleic acid of claim 106, wherein the single-stranded nucleic acid comprises a label.
111. The single-stranded nucleic acid of claim 106, wherein the single-stranded nucleic acid is chemically made at least in part.
112. A composition comprising a duplex formed between: (A) a single-stranded nucleic acid of between 18 and 103 contiguous nucleotides and comprising a nucleotide sequence selected from the group consisting of:(i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; and(B) an HIV-1 nucleic acid selected from the group consisting of:(a) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length gag polypeptide or its complement;(b) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length pol polypeptide or its complement;(c) an HIV-1 nucleic acid comprising a nucleotide sequence encoding a full-length env polypeptide or its complement; and(d) an HIV-1 nucleic acid comprising a nucleotide sequence for a long terminal repeat region comprising R and U3 regions or their complements;wherein the single-stranded nucleic acid of (A) does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid of (A) forms a duplex with the HIV-1 nucleic acid of (B);wherein the single-stranded nucleic acid of (A) consists of DNA;wherein the duplex is outside of a mammalian cell and outside of a viral particle;wherein the duplex comprises a double-stranded region of between 18 and 103 contiguous nucleotides and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein either the single-stranded nucleic acid or the duplex is bound to a solid support.
113. The composition of claim 112, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
114. The composition of claim 112, wherein the single-stranded nucleic acid is selected from the group consisting of (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
115. The composition of claim 112, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
116. The composition of claim 112, wherein the single-stranded nucleic acid comprises a label.
117. The composition of claim 112, wherein the single-stranded nucleic acid comprises a non-HIV-1 DNA nucleotide sequence.
118. The composition of claim 112, wherein the single-stranded nucleic acid is chemically made at least in part.
119. The composition of claim 112, wherein the single-stranded nucleic acid is bound to the solid support.
120. The composition of claim 112, wherein the duplex is bound to the solid support.
121. The composition of claim 112, wherein the HIV-1 nucleic acid is a full-length HIV-1 nucleic acid.
122. The composition of claim 112, wherein the HIV-1 nucleic acid is not a full-length HIV-1 nucleic acid.
123. A composition comprising: (A) a single-stranded nucleic acid of between 18 and 103 contiguous nucleotides and comprising a nucleotide sequence selected from the group consisting of:(i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; and(B) a compound selected from the group consisting of sodium saline citrate, formamide, and dextran sulfate;wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with an HIV-1 nucleic acid.
124. The composition of claim 123, wherein the single-stranded nucleic acid comprises a sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
125. The composition of claim 123, wherein the single-stranded nucleic acid is selected from the group consisting of: (i) a single-stranded nucleic acid consisting of from 18 to 103 nucleotides comprising a sequence of at least 18 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(ii) a single-stranded nucleic acid consisting of from 32 to 103 nucleotides comprising a sequence of at least 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iii) a single-stranded nucleic acid consisting of from 20 to 100 nucleotides comprising a sequence of at least 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region;(iv) a single-stranded nucleic acid comprising a sequence of at least about 32 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region; and(v) a single-stranded nucleic acid comprising a sequence of at least about 20 contiguous nucleotides from an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or from an HIV-1 long terminal repeat region.
126. The composition of claim 123, wherein the single-stranded nucleic acid is randomly generated from an HIV-1 nucleic acid.
127. The composition of claim 123, wherein the single-stranded nucleic acid comprises DNA.
128. The composition of claim 123, wherein the single-stranded nucleic acid comprises RNA.
129. The composition of claim 123, wherein the single-stranded nucleic acid is a cDNA.
130. The composition of claim 123, wherein the single-stranded nucleic acid comprises a label.
131. The composition of claim 123, wherein the single-stranded nucleic acid comprises a non-HIV-1 nucleotide sequence.
132. The composition of claim 123, wherein the single-stranded nucleic acid is chemically made at least in part.
133. The composition of claim 123, wherein the single-stranded nucleic acid is bound to a solid support.
134. A composition comprising a duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the duplex is outside of a mammalian cell and outside of an HIV-1 particle;wherein the duplex comprises a double-stranded region and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein the single-stranded nucleic acid comprises a label.
135. The composition of claim 134, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
136. The composition of claim 134, wherein the single-stranded nucleic acid comprises DNA.
137. The composition of claim 134, wherein the single-stranded nucleic acid comprises RNA.
138. A composition comprising a duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the duplex is outside of a mammalian cell and outside of an HIV-1 particle;wherein the duplex comprises a double-stranded region and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein either the duplex or the single-stranded nucleic acid is bound to a solid support.
139. The composition of claim 138, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
140. The composition of claim 138, wherein the single-stranded nucleic acid comprises DNA.
141. The composition of claim 138, wherein the single-stranded nucleic acid comprises RNA.
142. A composition comprising: a compound selected from the group consisting of sodium saline citrate, formamide, and dextran sulfate; anda duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid comprising a nucleotide sequence selected from the group consisting of:(i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the duplex is outside of a mammalian cell and outside of an HIV-1 particle;wherein the duplex comprises a double-stranded region and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region.
143. The composition of claim 142, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
144. The composition of claim 142, wherein the single-stranded nucleic acid comprises DNA.
145. The composition of claim 142, wherein the single-stranded nucleic acid comprises RNA.
146. A composition comprising a duplex formed between a Human Immunodeficiency Virus Type-1 (HIV-1) nucleic acid and a single-stranded nucleic acid comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) an HIV-1 nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543; wherein the single-stranded nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the single-stranded nucleic acid forms a duplex with the HIV-1 nucleic acid;wherein the duplex is outside of a mammalian cell and outside of an HIV-1 particle;wherein the duplex comprises a double-stranded region and a single-stranded region on either side of the double-stranded region that is longer than the double-stranded region; andwherein the single-stranded nucleic acid is attached to a non-HIV-1 nucleic acid through a covalent bond.
147. The composition of claim 146, wherein the single-stranded nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
148. The composition of claim 146, wherein the single-stranded nucleic acid comprises DNA.
149. The composition of claim 146, wherein the single-stranded nucleic acid comprises RNA.
150. A nucleic acid comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid; and wherein the nucleic acid is covalently attached to a solid support.
151. The nucleic acid of claim 150, wherein the nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
152. The nucleic acid of claim 150, wherein the nucleic acid comprises DNA.
153. The nucleic acid of claim 150, wherein the nucleic acid comprises RNA.
154. A nucleic acid comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the nucleic acid comprises a detectable label covalently attached to the nucleic acid; andwherein the detectable label is not an additional nucleic acid.
155. The nucleic acid of claim 154, wherein the nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
156. The nucleic acid of claim 154, wherein the nucleic acid comprises DNA.
157. The nucleic acid of claim 154, wherein the nucleic acid comprises RNA.
158. A nucleic acid comprising a nucleotide sequence selected from the group consisting of (i) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB2 having ATCC Accession No. 40231;(ii) a nucleotide sequence of either strand of viral DNA from lambda bacteriophage λ-HXB3 having ATCC Accession No. 40232;(iii) a nucleotide sequence of either strand of viral DNA from clone BH10 having ATCC Accession No. 40125;(iv) a nucleotide sequence of either strand of viral DNA from clone BH5 having ATCC Accession No. 40126;(v) a nucleotide sequence of either strand of viral DNA from clone BH8 having ATCC Accession No. 40127;(vi) a nucleotide sequence of either strand of viral DNA from clone pHXB3 having ATCC Accession No. 67081;(vii) a nucleotide sequence of either strand of viral DNA from clone pHXB-2D having ATCC Accession No. 67082;(viii) a nucleotide sequence of either strand of viral DNA from E. coli clone X10-1 having ATCC Accession No. 67083; and(ix) a Human Immunodeficiency Virus Type-1 (HIV-1) nucleotide sequence from the H9/HTLV-III cell line having ATCC Accession No. CRL 8543;wherein the nucleic acid does not form a duplex with HTLV-I and HTLV-II nucleic acids under conditions of stringency for hybridization under which the nucleic acid forms a duplex with an HIV-1 nucleic acid;wherein the nucleic acid is outside of a mammalian cell and outside of a viral particle; andwherein the nucleic acid is attached to a non-HIV-1 nucleic acid through a covalent bond.
159. The nucleic acid of claim 158, wherein the nucleic acid comprises a nucleotide sequence which is part of an HIV-1 gag open reading frame, an HIV-1 pol open reading frame, an HIV-1 env open reading frame or part of an HIV-1 long terminal repeat region.
160. The nucleic acid of claim 158, wherein the nucleic acid comprises DNA.
161. The nucleic acid of claim 158, wherein the nucleic acid comprises RNA.

REFERENCE TO RELATED APPLICATIONS

This application, Ser. No. 08/385,231, filed Feb. 8, 1995, is a file wrapper continuation of patent application Ser. No. 07/832,603, filed Feb. 12, 1992, now abandoned, which is a file wrapper continuation of patent application Ser. No. 07/160,827, filed Feb. 26, 1988, now abandoned, which is (i) a continuation-in-part of patent application Ser. No. 07/033,891, filed Apr. 3, 1987, now abandoned, which is a continuation of patent application Ser. No. 06/643,306, filed Aug. 22, 1984, now abandoned, (ii) a continuation-in-part of patent application Ser. No. 06/693,866, filed Jan. 23, 1985, pending, which is a continuation-in-part of patent application Ser. No. 06/659,339, filed Oct. 10, 1984, now abandoned, which is a continuation-in-part of patent application Ser. No. 06/643,306, filed Aug. 22, 1984, now abandoned, and (iii) a continuation-in-part of patent application Ser. No. 06/813,069, filed Dec. 24, 1985, now abandoned, the disclosures of which are incorporated herein by reference in their entirety for all purposes.

US Referenced Citations (57)

Number	Name	Date	Kind
4401756	Gillis	Aug 1983	A
4520113	Gallo	May 1985	A
4647773	Gallo	Mar 1987	A
4652599	Gallo	Mar 1987	A
4665032	Laurence	May 1987	A
4689398	Wu	Aug 1987	A
4692403	Lindner	Sep 1987	A
4707439	Seto	Nov 1987	A
4716102	Levy	Dec 1987	A
4725669	Essex	Feb 1988	A
4738922	Haseltine	Apr 1988	A
4743678	Essex	May 1988	A
4839288	Montagnier	Jun 1989	A
4883813	Maxim	Nov 1989	A
4886743	Hood	Dec 1989	A
4892865	Townsend	Jan 1990	A
4910132	Knight	Mar 1990	A
4925784	Crowl	May 1990	A
4931393	Martin	Jun 1990	A
4935372	Goh	Jun 1990	A
4950652	Carter	Aug 1990	A
4957737	Heimer	Sep 1990	A
4963497	Wong-Staal	Oct 1990	A
4981790	Haseltine	Jan 1991	A
4985249	Sakagami	Jan 1991	A
5008182	Sninsky	Apr 1991	A
5019510	Wain-Hobson	May 1991	A
5024940	Brenner	Jun 1991	A
5025800	Zelson	Jun 1991	A
5026635	Ferguson et al.	Jun 1991	A
5030714	Alizon	Jul 1991	A
5030718	Montagnier	Jul 1991	A
5034511	Alizon	Jul 1991	A
5039604	Papsidero	Aug 1991	A
5043262	Haseltine	Aug 1991	A
5047435	Lavie	Sep 1991	A
5051496	Alizon	Sep 1991	A
5053509	Antoine	Oct 1991	A
5055391	Montagnier	Oct 1991	A
5063053	Wong-Staal	Nov 1991	A
5064946	Shaver	Nov 1991	A
5066579	Reyes	Nov 1991	A
5066782	Montagnier	Nov 1991	A
5070012	Nolan	Dec 1991	A
5079342	Alizon	Jan 1992	A
5087557	McClure	Feb 1992	A
5087625	Hargrave	Feb 1992	A
5098833	Lasky	Mar 1992	A
5098927	Takatsuki	Mar 1992	A
5104790	Flesher	Apr 1992	A
5108904	Landay	Apr 1992	A
5108920	Ng	Apr 1992	A
5109123	Reinherz	Apr 1992	A
6531276	Luciw	Mar 2003	B1
7393949	Luciw	Jul 2008	B1
RE41158	Luciw	Mar 2010	E
8329396	Alizon	Dec 2012	B1

Non-Patent Literature Citations (54)

Entry
Barré-Sinoussi, et al. Science 220 : 868, 1983.
Popovic, et al. Science 224 : 497, 1984.
Gelmann, et al. PNAS USA 81 : 993, 1984.
Stratowa, et al EMBO J. 1(12) : 1573, 1982 Fuisawa, et al. Gene 40 : 23, 1985.
G.M. Shaw et al (1984) Science 226 : 1165-1171.
M. Alizon et al (1986) Cell 46 : 63-74.
Y. Koyanagi et al (1987) Science 236 : 819-822.
W.A. Haseltine (1991) Science 253 : 366.
A. G. Fisher et al (1985) Nature 316 : 262-265.
E. Terwilliger et al (1986) 60 : 754-760.
Nature-Based Products Examples, attached, available at http://www.uspto.gov/patents/law/exam/mdc—examples—nature-based—products.pdf, accessed Nov. 25, 2015.
Merriam-Webster (definition of “bind,” attached, available at http://beta.merriam-webster.com/dictionary /bind, accessed Nov. 25, 2015).
George M. Shaw et al., “Molecular Characterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III in the Acquired Immune Deficiency Syndrome,” Science, vol. 226, pp. 1165-1171, Dec. 7, 1984.
Alice Corporation Pty. Ltd. v. CLS Bank International et al., U.S. Supreme Court, No. 13-298; Decided Jun. 19, 2014.
Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al.; U.S. Supreme Court, No. 12-398; Decided Jun. 13, 2013.
Mayo Collaborative Services, DBA Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc.; U.S. Supreme Court, No. 10-1150; Decided Mar. 20, 2012.
Bilski et al. v. Kappos, Under Secretary Ofcommerce for Intellectual Property and Director, Patent and Trademark Office; U.S. Supreme Court, No. 08-964; Decided Jun. 28, 2010.
University of Utah Research Foundation, The Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, Endorecherche, Inc., and Myriad Genetics, Inc. v. Ambry Genetics Corporation; Fed. Cir. 2014-1361, -1366; Decided Dec. 17, 2014.
In Re Roslin Institute (Edinburgh); Fed. Cir. 2013-1407; Decided May 8, 2014.
Classen Immunotherapies, Inc., v. Biogen Idec, and Glaxosmithkline, and Merck & Co., Inc., and Chiron Corporation, Kaiser-Permanente, Inc., Kaiser Permanente Ventures, Kaiser Permanente International, Kaiser Permanente Insurance Company, The Permanente Federation, LLC, The Permanente Company, LLC, The Permanente Foundation, The Permanente Medical Group, Inc., Kaiser Foundation Hospitals, Kaiser Foundation Added Choice Health Plan, Inc., and Kaiser Foundation Health Plan Inc.; Fed. Cir. 2006-1634,-1649; Decided Aug. 31, 2011.
U.S. Appl. No. 06/693,866, filed Jan. 23, 1985, Chang.
Alizon M., etal.; “Genetic Variability of the AIDS Virus: Nucleotide Sequence Analysis of Two Isolates from African Patients”; Cell, vol. 225, Aug. 31, 1984; pp. 927-930.
Arya S.K., et al.; “Homology of Genome of AIDS-Associated Virus with Genomes of Human T-Cell Leukemia Viruses”; Science, vol. 225, Aug. 31, 1984; pp. 927-930.
Barre-Sinoussi, F. etal.; “Isolation of a T-Lymphotropic retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)”; Science, vol. 220, May 20, 1983; pp. 868-870.
Chang, N.T., et al.; :Expression in Escherichia coli of Open Reading Frame Gene Segments of HTLV-III; Science., vol. 228, 1985; pp. 93-96.
Dowbenko D.J., et al.; “Bacterial expression of the acquired immunodeficiency syndrome retrovirus p24 gag protein and its use as a diagnostic reagent”; Proc. Natl. Acad. Sci. USA., vol. 82, Nov. 1985; pp. 7748-7752.
Essex M.; “Adult T-Cell Leukemia-Lymphoma: Role of a Human Retrovirus”; Journal of National Cancer Institute, vol. 69, No. 4, Oct. 4, 1982; pp. 981-985.
Feorino P.M., et al.; “Lymphadenopathy associated virus infection of a blood donor-recipient pair with acquired immunodeficiency syndrome”; Science., vol. 225, Jul. 6, 1984; pp. 69-72.
Fisher, A.G., et al.; “A molecular clone of HTLV-III with biological activity”; Nature., vol. 316, Jul. 18, 1985; pp. 262-265.
Fujisawa Y., et al.; “Expression of hepatitis B virus surface antigen P31 gene in Escherichia coli”; Gene., vol. 40, 1985; pp. 23-29.
Gelmann, E.P.; “Molecular cloning of a unique human T-cell leukemia virus (HTLV-IIMo)”; Proc. Nat!. Acad. Sci. USA., vol. 81, Feb. 1984; pp. 993-997.
Genbank: K02011.1; “HIV-1 isolate BH8 tat protein and rev protein genes, partial cds; vpu protein and envelope protein precursor, genes, complete cds; and long terminal repeat, partial sequence”; http://www.ncbi.nlm.nih.gov/nuccore/327466, Jul. 9,1999; 4 pages.
Genbank: K02012.1; “Human immunodeficiency virus type 1, isolate BH5, gag, pol vif, and vpr genes”; http://www.ncbi.nlm.nih.gov/nuccore/327459, Aug. 2, 1993; 5 pages.
Genbank: M15654.1; “Human immunodeficiency virus type 1, isolate BH10, genome”; http://www.ncbi.nlm.nih.gov/nuccore/326383, Aug. 2, 2006; 7 pages.
Hahn, B.H., et al.; “Molecular cloning and characterization of the HTLV-III virus associated with AIDS”;Nature., vol. 312, Nov. 8, 1984; pp. 166-169.
Haseltine, W.A.; “HIV Research and nef Alleles”; Science, vol. 253, 1991; p. 366.
Klatzmann D., et al.; “T-Iymphocyte T4 molecule behaves as the receptor for human retrovirus LAV”; Nature., vol. 312, Dec. 20, 1984; pp. 767-768.
Koyanagi Y., et al.; “Dual Infection of the Central Nervous System by AIDS Viruses with Distinct Cellular Tropisms”; Science, vol. 236, May 15, 1987; pp. 819-822.
Manzari V., et al.; “Human T-cell leukemia-lymphoma virus (HTLV): cloning of an integrated defective provirus and flanking cellular sequences”; Proc. Nat!. Acad. Sci. USA, vol. 80, No. 12, Jun. 1, 1983; pp. 1574-1578.
Marx J.L.; “A Virus by Any Other Name . . .”; Science, Mar. 22, 1985; in AIDS Papers from Science, 1982-1985, ed. Ruth Kulstad, 1986, pp. 450-454.
Merriam Webster; (definition of “bind,” available at http://beta.merriam-webster.com/dictionary/bind, accessed Nov. 25, 2015).
Muesing, M.A., et al.; “Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus”; Nature., vol. 313, Feb. 7, 1985; pp. 450-458.
Nature-Based Products Examples; available at http://www.uspto.gov/patents/law/exam/mdc-examples-nature-based-products.pdf, accessed Nov. 25, 2015.
Patent Interference No. 105,291; “Decision-Priority—BD.R. 125(a)”; Sep. 28, 2007; 33 pages.
Patent Interference No. 105,291; “Judgment—Merits—BD.R. 127”; Sep. 28, 2007; 3 pages.
Popopvic M. et al.; “Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with Aids and Pre-AIDS”; Science., vol. 224, May 4, 1984; pp. 497-500.
Ratner, L., etal.; “Complete nucleotide sequence of the AIDS virus, HTLV-III”; Nature., vol. 313, Jan. 24, 1985; pp. 277-284.
Seiki M., et al.; “Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure”; Proc. Natl. Acad. Sci. USA, vol. 79, No. 22, Nov. 1, 1982; pp. 6899-6902.
Seiki M., et al.; “Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA”; Proc. Natl. Acad. Sci. USA, vol. 80, No. 12, Jun. 1, 1983; pp. 3618-3622.
Shaw, G.M., etal.; “Molecular Characterization of Human T-Cell Leukemia (Lymphotropic) Virus Type III in the Acquired Immune Deficiency Syndrome”; Science., vol. 226, Dec. 7, 1984; pp. 1165-1171.
Stratowa C. al.; “Recombinant retroviral DNA yielding high expression of hepatitis B surface antigen”; EMBO J., vol. 1 No. 12, 1982; pp. 1573-1578.
Terwilliger E., et al; “Effects of Mutations within the 3' orf Open Reading Frame Region of Human T-Cell Lymphotropic Virus Type III (HTLV-III/LAV) on Replication and Cytopathogenicity”; J. Virol., vol. 60, No. 2, Nov. 1986; pp. 754-760.
Ariosa Diagnostics, Inc., Natera, Inc., DNA Diagnostics Center, Inc., v. Sequenom, Inc., Sequenom Center for Molecular Medicine, LLC, ISIS Innovation Limited; Fed Cir. 2014-1139, 2014-1144; Decided: Jun. 12, 2015 (2015).
Ariosa Diagnostics, Inc., Natera, Inc., DNA Diagnostics Center, Inc., v. Sequenom, Inc., Sequenom Center for Molecular Medicine, LLC, ISIS Innovation Limited; Fed Cir. 2014-1139, 2014-1144; Decided: Dec. 2, 2015 (2015).

Continuations (3)

	Number	Date	Country
Parent	07832603	Feb 1992	US
Child	08385231		US
Parent	07160827	Feb 1988	US
Child	07832603		US
Parent	06643306	Aug 1984	US
Child	07033891		US

Continuation in Parts (5)

	Number	Date	Country
Parent	07033891	Apr 1987	US
Child	07160827		US
Parent	06813069	Dec 1985	US
Child	07160827	Feb 1988	US
Parent	06693866	Jan 1985	US
Child	06813069		US
Parent	06659339	Oct 1984	US
Child	06693866		US
Parent	06643306	Aug 1984	US
Child	06659339		US

Molecular cloning of HIV-1 from immortalized cell lines

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications